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[57] ABSTRACT 
Compounds useful as inhibitors of the enzyme elastase 
are of the following general formula: 
11 
Z-Ala-Ala-Pro-Clh-N-C-XR 
R, 
wherein Z is selected from the group consisting of 
R"O—~Suc-- where R” is lower alkyl of 1 to 3 carbon 
atoms and CF3CO--; X is oxygen or sulfur; R’ is se 
lected from the group consisting of straight or second 
ary branch-chained alkyl of 1 to 4 carbon atoms, alkenyl 
of 2 to 3 carbon atoms, alkynyl of 2 to 4 carbon atoms, 
cycloalkyl of 3 to 6 carbon atoms, and benzyl, and R is 
selected from the group consisting of susbstituted or 
unsubstituted phenyl wherein the substituents are se 
lected from the group consisting of nitro, and penta 
fluoro; benzyl, CHZCFZCFZCF 3, l-lower alkyl tetrazo 
lyl, l-phenyltetrazolyl, 2-thioxo-3-thiazolidinyl-, pyri 
dyl and benzothiazolyl, provided that when R is parani 
trophenyl, R’ is other than tertiary-butyl, benzyl or 
cyclohexyl, and when X is sulfur, R is other than ben 
zyl. 
30 Claims, No Drawings 
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PEPTIDE ELASTASE INHIBITORS AND 
METHODS 
FIELD OF THE INVENTION 
This invention relates to inhibitors of the enzyme 
elastase and more particularly relates to the use of cer 
tain novel peptides containing the carbamate functional 
ity which are active-site directed inhibitors of the en 
zyme elastase. 
BACKGROUND OF THE INVENTION 
Proteinases from polymorphonuclear leukocytes and 
macrophages, especially elastases (human leukocyte 
elastase and cathepsin G), appear to be responsible for 
the chronic tissue destruction associated with inflamma 
tion, arthritis and emphysema. During infection or in 
?ammation, the normal lung is protected from proteo 
lytic digestion by the protease inhibitor, ai-antitrypsin. 
The protective mechanism appears to be nonoperative 
in individuals with an ai-antitrypsin de?ciency due to 
genetic or other causes. Synthetic elastase inhibitors 
capable of replacing al-antitrypsin therefore appear to 
be useful in the treatment of pulmonary emphysema and 
related diseases. 
Several types of elastase inhibitors have been re 
ported in the literature. These include peptide chloro 
methyl ketones as described in “Inhibition of Human 
Leukocyte Elastase by Peptide Chloromethyl Ke 
tones”, P. M. Tuhy and J. C. Powers, FEBS Letters, 50, 
359-61 (1975); “Speci?city of Porcine Pancreatic Elas 
tase, Human Leukocyte Elastase and Cathepsin G. Inhi 
bition with Peptide Chloromethyl Ketones”, J. C. Pow 
ers, B. F. Gupton, A. D. Harley, N. Nishino and R. J. 
Whitley, Biochem. Biophys. Acto. 485, 156-66 (1977); 
azapeptides “Proteinase Inhibitors. 1. Inhibitors of Elas 
tase”, C. P. Dorn, M. Zimmerman, S. S. Yang, E. C. 
Yurewicz, B. M. Ashe, R. Frankshun and H. Jones, J. 
Med. Chem, 20, 1464-68 (1977); “Reaction of Serine 
Proteases with Aza-amino Acid and Ala-peptide De 
rivatives”, J. C. Powers and B. F. Guptcn, Meth. En 
zymol, 46, 208-16 (1977); sulfonyl ?uorides “Speci?city 
and Reactivity of Human Leukocyte Elastase, Porcine 
Pancreatic Elastase, Human Granulocyte Cathepsin G, 
and Bovine Pancreatic Elastase, Human Granulocyte 
Cathepsin G, and Bovine Pancreatic Chymotrypsin 
with Arylsulfonyl Fluorides. Discovery of a new series 
of potent and speci?c irreversible Elastase Inhibitors”, 
T. Yoshimura, L. N. Barker and J. C. Powers, J. Biol. 
Chem., 257, 5077-84 (1982); heterocyclic acrylating 
agents-”Inhibition of Elastase and Other Serine Pro 
teases by Heterocyclic Acylating Agents”, M. Zimmer 
man, I-I. Morman, D. Mulvey, H. Jones, R. Frankshun 
and B. M. Ashe, J. Biol. Chem, 255, 9848-51 (1980); 
“Selective Inhibition of Human Leukocyte Elastase and 
Bovine oil-Chymotrypsin by Novel Heterocycles”, B. 
M. Ashe, R. L. Clark, H. Jones and M. Zimmerman, J. 
Biol. Chem, 256: 11603-6 (1981); imidazole N-carboxa 
mides, W. C. Groutas, R. C. Badger, T. D. Ocain, D. 
Felker, J. Frankson and M. Theodorakis, Biochem. Bio 
phys. Res. Commun., 95, 1890 (1980); and p-nitrophenyl 
N alkyl carbamates, “p-Nitrophenyl Carbamates as 
Active-Site-Speci?c Reagents for Serine Proteases”, R. 
E. Sco?eld, R. P. Werner and F. Wold, Biochemistry, 
16, 2492 (1977). ' 
Although some peptide chloromethyl ketones have 
been shown to be effective in preventing elastase in 
duced emphysema in animal models “Prevention of 
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Elastase Induced Experimental Emphysema by Oral 
Administration of a Synthetic Elastase Inhibitor,”, A. 
Janoff and R. Dearing, Am. J. Respir. Dis., 121, 1025-3 
(1980), there 'is considerable question whether such 
reactive agents could be used for treating emphysema in 
humans. This is not surprising since the alkylating moi 
eties in these inhibitors might render them toxic when 
used on a continuous basis. To be suitable for human 
use, an~ enzyme inhibitor has to show a high degree of 
selectively and must have minimal toxic side effects. As 
a result, most drugs are molecules that reversibly bind 
to speci?c enzymes or receptor sites. Examples are the 
carbamate esters physostigmine and neostigmine which 
have been clinically used as inhibitors of acetyl choline 
esterases, A. G. Gilman, L. S. Goodman, and A. 
Gilman, “The pharmacological Basis of Therapeutics”, 
p. 101, MacMillan Publishing Co. (1980). 
There accordingly remains a need in the art for com 
pounds which are speci?c and active-site directed inhib 
itors of the enzyme elastase which are not subject to the 
disadvantages of compounds known in the art for this 
purpose. 
SUMMARY OF THE INVENTION 
It is accordingly one object of the present invention 
to provide novel compounds which are inhibitors of the 
enzyme elastase. 
A further object of the invention is to provide spe 
ci?c active-site directed inhibitors of the enzyme elas 
tase which are substituted carbamates. 
A still further object of the invention is to provide 
methods for the speci?c inhibition of porcine pancreatic 
elastase and human leukocyte elastase by substituted 
carbamate compounds without affecting the similar 
serine dependent proteases, bovine pancreatic trypsin 
and chymotrypsin. 
An even further object of the invention is to provide 
pharmaceutical compositions useful in the speci?c inhi 
bition of porcine pancreatic elastase, said compositions 
containing as the active and effective component, cer 
tain substituted and novel carbamate compounds. 
Further objects and advantages of the present inven 
tion will become apparent as the description thereof 
proceeds. ~ 
In satisfaction of the foregoing objects and advan 
tages, the present invention provides substituted carb 
mate compounds of the following formula: 
II 
Z--Ala-Ala—-Pro-CIh-Iil-C-X-R 
R. 
wherein Z is selected from the group consisting of 
R"O—Suc—where R” is lower alkyl of 1 to 3 carbon 
atoms, and CF3CO—; X is oxygen or sulfur, R’ is se 
lected from the group consisting of straight or second 
ary branch-chained alkenyl of 2 to 4 carbon, atoms, 
alkynyl of 2 to 4 carbon atoms, alkyl of l to 4 carbon 
atoms, cycloalkyl of 3 to 6 carbon atoms, preferably 
cyclopropyl or cyclohexyl, and benzyl, and R is se 
lected from the group consisting of substituted or un 
substituted phenyl wherein the substituents are selected 
from the group consisting of nitro, preferably p-nitro, 
and fluoro, preferably pentafluoro; benzyl, 
CH2CF2CF2CF3, l-lower alkyl- and l-phenyl tetrazo 
lyl-, 2-thioxo-3-thiazolindinyl-, pyridyl, and benzo 
4,643,991 
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thiazolyl, provided that when R is para-nitrophenyl, R’ 
is other than tertiary-butyl, benzyl, or cyclohexyl, and 
when X is sulfur, R is other than benzyl. 
The invention also provides elastase inhibiting phar 
maceutical compositions containing these novel substi 
tuted carbamates as the active ingredients, methods for 
inhibiting the enzyme elastase in animals and humans, 
and methods for production of the compounds and 
compositions. 
DESCRIPTION OF PREFERRED 
EMBODIMENTS 
As pointed out above, the invention relates to certain 
novel substituted carbamate compounds, pharmaceuti 
cal compositions containing these compounds, and 
methods for use of these pharmaceutical compositions 
in the speci?c inhibition of porcine pancreatic elastase 
and human leukocyte elastase without affecting the 
similar serine dependent proteases, bovine pancreatic 
trypsin and chymotrypsin. It is known from the art that 
proteases from polymorphonuclear leukocytes and 
macrophages, especially elastases (human leukocyte 
HL elastase and cathepsin G) appear to be responsible 
for the chronic tissue destruction associated with in 
?ammation, arthritis and emphysema. During infection 
or in?ammation, the normal lung is protected from 
proteolytic digestion by the protease inhibitor, ctr-ani 
trypsin. This protective mechanism appears to be non 
operative in individuals with an al-antitrypsin de? 
ciency due to genetic or other causes. Synthetic elastase 
inhibitors capable of replacing al-antitrypsin are there 
fore useful in the treatment of pulmonary emphysema 
and related diseases. 
According to the present invention, a class of com 
pounds containing carbamate functionality and oligo 
peptides have been found to be active-site directed in 
hibitors of elastase in animals and humans. This class of 
compounds therefore provide an opportunity to incor 
porate chemical moieties which will optimize the affin 
ity of the inhibitor towards the enzyme, and transfer 
and acylating moiety to the active site of the enzyme. 
The nature of the acylating moiety could be varied to 
optimize the duration of enzymatic inactivation. 
It is theorized that the mechanism of the invention 
takes advantage of the fact that the carbamate esters 
will react with proteases and esterases at the carbonyl 
carbon by losing the alkoxy portion and transferring the 
carbamylating moiety to the active site of the enzyme. 
Decylation will then lead to recovery of enzymatic 
activity. 
The present invention provides a series of carbamate 
compounds which are active in accordance with the 
above proposals as elastase inhibitors. These com 
pounds are carbamates substituted by oligopeptides and 
may generally be described by the following general 
formula: 
wherein Z is selected from the group consisting of 
R"O—Suc—where R" is lower alkyl of l to 3 carbon 
atoms, and CF3CO-—; X is oxygen or sulfur, R’ is se 
lected from the group consisting of straight or second 
ary branched-chain alkyl of l to 4 carbon atoms, alkenyl 
of 1 to 4 carbon atoms, alkynyl of 2 to 4 carbon atoms, 
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cycloalkyl of 3 to 6 carbon atoms, preferably cyclopro 
pyl or cyclohexyl, and benzyl, and R is selected from 
the group consisting of substituted or unsubstituted 
phenyl wherein the substituents are selected from the 
group consisting of nitro, preferably p-nitro, and ?uoro, 
preferably penta?uoro; benzyl, Cl-lzCF2CF2CF3, 1 
lower alkyl tetrazolyl-, l-phenyltetrazolyl-, 2-thioxo-3 
thiazolindyl, pyridyl, and benzothiazolyl, provided that 
when R is paranitrophenyl, R’ is other than tertiary 
butyl, benzyl or cyclohexyl, and when X is sulfur, R is 
other than benzyl. 
In more preferred and detailed embodiments, the 
compounds of the invention may be described by the 
following general formulae A or E: 
wherein X is oxygen or sulfur and R is selected from the 
group consisting of phenyl, ?uorophenyl, nitrophenyl, 
l-phenyltetrazolyl, l-lower alkyl tetrazolyl, benzyl, 
3-thiazolidinyl, pyridyl, and benzothiazolyl, and R’ is 
straight or secondary branch chained alkyl of 2 to 4 
carbons, alkenyl of 2 to 4 carbons, and alkynyl of 2 to 4 
carbons, provided that when R is p-nitrophenyl, R’ is 
other than tertiarybutyl, and when X is sulfur, R is other 
than benzyl; and 
wherein Z is selected from the group consisting of 
MeO-Suc-Ala-Ala and CF3CO-Ala-Ala, wherein R' is 
as de?ned above but is preferably isopropyl. 
It will be noted from the description of the com 
pounds that the peptidyl carbamates of this invention 
are those wherein the amino portion contains the oligo 
peptide and the peptide portion is so chosen as to in 
crease the speci?city of the carbamate ester for elastase. 
In one embodiment, the compounds of the invention 
are prepared by a sequential series of reactions begin 
ning with L-proline protected on the ring nitrogen with 
ultimate coupling to the peptide. In the ?rst step, an 
N-protected proline, e.g., N-t-BOC-L-proline, is re 
acted with diazomethane to obtain the diazoketone 
followed by treatment with HCL to obtain the chloro 
methyl ketone protected L-proline. The chloromethyl 
ketone thus obtained is reacted with the appropriate 
amine HZNR' to form the protected amine derivative. 
The amine is in turn reached with the appropriate chlo 
roformate or thiochloroformate and deprotected by 
reaction with an acid such as HCl to provide the HCl 
salt. This compound is then coupled with Z-Ala-Ala by 
the mixed carbonic anhydride method to provide the 
compounds of the invention. The Z-Ala-Ala com 
pounds are obtained by reaction of Ala-Ala with methyl 
succinic acid N-hydroxy succinimide ester when 
Z=R"O—-Suc, e.g., MeOSuc. These Z-Ala-Ala inter 
mediates may be prepared according to the following 
scheme: 
5 
o ' 1. 
\\ 
HO-—N 
u ii 0” 
mo-ccmcmcct —---> 
0 
t’ t’ ‘ mo-ccmcmc-o-mij ALL-?e 
// 
II II 
MeO-CCH2CH2C— Ala-"Ala 
In conducting these reactions, the L-proline in the 
initial step is protected on the ring nitrogen by reaction 
with any suitable protective agent known to the art so 
that reaction will occur on the carboxylic acid portion 
of the molecule. Preferably, the nitrogen atom in the 
ring is protected with a known protective agent, such as 
t-BOC. For example, t-BOC-Pro is available commer 
cially from Sigma Chemical Company, St. Louis, M0. 
The protected proline is reacted with diazomethane by 
the method of Penke et al. (B. Penke, J. Czombos, L. 
Balaspiri, J. Peters and K. Kovacs, Helv. Chim. Acta., 
53, 1057 (1970). Thereafter, the resulting chloromethyl 
ketone is then reacted with the appropriate amine. This 
reaction is preferably conducted in a solvent solution, 
such as a lower alkyl alcohol, and preferably in the 
presence of an alkali metal iodide. The reactants are 
mixed under cool temperatures and then reacted at 50° 
to 75° C. to complete the reaction. The evolved HCl is 
neutralized, as with a sodium carbonate solution, and 
extracted. This intermediate is then reacted with the 
appropriate chloroformate or thiochloroforrnate and 
deprotected with hydrogen chloride to form the carba 
mate portion of the molecule. This molecule is then 
coupled with the peptide portion of the molecule to 
form the ?nal product. 
This reaction procedure may be illustrated as follows: 
E H. 
CH N 
t-Boc-UCOH 4'29 
ii 
t-Boc-UCCHNZ 3% 
o 
_ “ Nal 
t-Boc UGO-12C] W 
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-continued 
R, 
ll 
MeOSue-Ala-Ala-Pro-Clh-III-C-XR 
R. 
As pointed out above, the compounds of the inven 
tion may be employed as speci?c active site directed 
inhibitors of the enzyme, elastase. For this purpose, the 
compounds are preferably combined with a pharmaceu 
tically acceptable carrier for administration by injection 
or in the oral form. Conventional adjuvants and carriers 
may be employed in combination with about 0.001 to 
2.0 weight percent of the active compound. The com 
pounds may be administered to animals or humans at 
dosage amounts ranging from about 1 mg/kg up to 
about 10 mg/kg, preferably an average amount of about 
6 mg/kg. 
The following examples illustrate preferred embodi 
ments of the invention but the invention is not consid 
ered to be limited thereto. In the examples and through 
out this speci?cation, parts are by weight unless other 
wise indicated. 
In synthesis of the compounds of the invention, melt 
ing points were determined on a Thomas-Hoover Uni 
Melt apparatus and are uncorrected. ‘H NMR spectra 
were obtained using a Varian EM-360 (60 MHZ) or 
EM-390 (90_ MH;) spectrometer. Infrared (IR) spectra 
were recorded on a Perkin-Elmer 567 spectrophotome 
ter. Microanalyses were performed by Atlantic Mi 
crolab, Inc., Atlanta, Ga. or by Micro Analysis, Inc., 
Wilmington, Del. 
Reactions were routinely followed by thin layer 
chromatography (TLC) using Whatman MK6F silica 
gel plates. Spots were detected by UV (254 nm), iodine 
or HBr-Ninhydrin spraying. Column chromatography 
was carried out using Silica Gel 60 from E. Merck, 
Darmstadt, Germany. All compounds were identi?ed 
by spectral data and elemental analysis. 
EXAMPLE 1 
Methyl Succinic Acid-N-hydroxysuccinimide Ester 
To an ice-cooled solution of N-hydroxysuccinimide 
(1.15 g, 10 mmol) and methyl succinyl chloride (1.23 ml, 
10 mmol) in ethyl acetate (50 ml) was added, dropwise, 
triethyl amine (1.4 ml, 10 mmol). The mixture was . 
stirred at 4° C. for 10 min and at room temperature for 
5 min. Filtration of insoluble materials, followed by the 
evaporation of the ?ltrate yielded pale yellow crystals. 
(2.1 g, 92%); mp. 86°-88° C. 
4,643,991 
7 
EXAMPLE 2 
Methyl Succinyl-L-alanyl-L-alanine 
Without further puri?cation, the product from Exam 
ple 1, (1.48 g, 6.46 mmol), was slowly added to a stirred 
solution of L-alanyl-L-alanine (862 mg, 5.38 mmol) and 
sodium bicarbonate (452 mg, 5.38 mmol) in water (5 ml) 
and acetone (5 ml). The mixture was stirred at room 
temperature for 4 h, and the acetone evaporated. The 
aqueous solution was washed with EtOAC (8 ml), acidi 
?ed with citric acid (1.3 g), saturated with NaCl, and 
extracted four times with EtOAc (30 ml). The organic 
layers were washed with NaCl solution (3 ml) succes~ 
sively, combined, dried over anhydrous MgSO4, and 
evaporated. The residue was washed with EtOAc to 
give colorless crystals of methyl succinyl-L-alanyl-L 
alanine, (920 mg, 62%); m.p. 134°-135° C. NMR 
(DMSO-d6)'a 1.16 (d, 3H, J=7 Hz), 1.24 (d, 3H, J =7 
Hz), 2.40 (t, 4H, J =7 Hz), 3.54 (S, 3H), 4.16 (quintet, 
1H, J =7 Hz), 4.29 (quintet), 1H, J =7 Hz), 8.01 (d, 2H, 
J =7 Hz) ppm; IR (Nujol) 3280, 1735, 1690, 1630, 1540 
cm-1. Analysis calculated for C11H13N206: C, 48.17; 
H, 6.61; N, 10.21. Found: C, 48,05; H, 6.65; N, 10.17. 
EXAMPLE 3 
(N-t-Boc-L-prolyl)Diazomethane 
This compound was prepared according to the 
method of Penke et al, Helv. Chim. Acta. 53, 1057 
(1970). 
EXAMPLE 4 
(N-t-Boc-L-prolyl)Chloromethyl Ketone 
Into an ice-cooled solution of the product of Example 
3, (11.0 g) in ether (240 ml), HCl gas was introduced 
until the yellow solution turned colorless. The mixture 
was evaporated and puri?ed by column chromatogra 
phy (hexane/CHClg; 1:1) to give colorless crystals, (9.8 
g, 51.7% from t-Boc-L-proline); m.p. 47°-49° C.; NMR 
(CDC13) & 1.47 (s, 9H), 1.8-2.2 (m, 4H), 3.4-3.8 (m, 
2H), 4.36 (s, 2H), 4.4-4.8 (m, 1H); IR (Film) 1735, 1690 
Cm_1. Anal Calcd for C11H1gClNO3: C, 53.33; H, 732; 
n, 5.65; Cl, 14.31. Found: C, 53.46; H, 735; N, 5.56; Cl, 
14.26. 
EXAMPLE 5 
N-(N'-t-Boc-L-prolyl)Methyl-N-Isopropylamine 
To an ice-cooled solution of the product of Example 
4, (3.0 g, 12.1 mmol) in 95% EtOH (30 ml), was added 
sodium iodide (1.95 g, 12.8 mmol) and isopropylamine 
(10.2 ml, 60 mmol). The mixture was shaken at 65° C. 
for 15 h and a saturated NaHCO3 solution was added. 
The mixture was extracted into ether, evaporated and 
puri?ed by column chromatography (CHC13.CH3OH; 
50:1) to give a brown oil, (1.84 g, 56%). NMR (CDC13) 
& 1.12 (d, 6H, J=6 Hz), 1.50 (s, 9H), 1.8-2.2 (m, 4H), 
2.5-3.1 (m, 3H), 3.4-3.8 (m, 3H), 4.3-4.6 (m, 1H), IR 
(Film) 3330 (br), 1695 (br) cm-l. 
EXAMPLE 6 
p-Nitrophenyl 
N-(N’-t-Boc-L-prolyl)Methyl-N-Isopropylcarbamate 
A solution of p-nitrophenyl chloroformate (0.88 g, 
4.34 mmol) in dry THF (10 ml) was added dropwise to 
a solution of the product of Example 5, 10.98 g, 3.36 
mmol) and triethylamine (0.604 ml, 4.34 mmol) in THF 
at 5° C. The mixture was stirred at 5° C. for 2 h and 
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?ltered. The ?ltrate was evaporated and puri?ed by 
column chromatography (CHCl3/E1OAC; 100:1) to 
give a yellow oil (1.28 g, 81%). NMR (CDC13) & 
1.0-1.3 (m, 6H), 1.3-1.5 (m, 9H), 1.7-2.2 (m, 4H), 
3.3-3.7 (m, 2H), 4.0-4.7 (m, 4H), 7.1-7.4 (m, 2H), 
8.1-8.4 (m, 2H); IR (Film) 1690-1740, 1590, 1520 cm* 1. 
EXAMPLE 7 
Phenyl N-(N’-t-Boc-L-Prolyl)Methyl-N-Isopropyl 
Carbamate 
This compound was prepared using the procedure of 
Example 6 and the product of Example 5 as starting 
material, Yield, 95%; NMR (CDCl3) & 1.1-1.4 (m, 6H), 
1.47 (s, 9H), 1.7-2.1 (m, 4H), 3.4-3.7 (m, 2H), 3.8-4.6 
(m, 4H), 7.0-7.5 (m, 5H); IR (Film) 1680-1750, 1595 
cm-1. 
EXAMPLE 8 
p-Nitrophenyl N-(L-Prolymethyl)-N-Isopropyl 
Carbamate Hydrochloride 
A mixture of the product of Example 6 (1.65 mmol) in 
formic acid (5 ml) and 1N solution hydrogen chloride in 
THF (2 ml) was stirred at room temperature for 1 h. 
The mixture was evaporated and the oil obtained was 
triturated with EtzO to give the desired compound as 
crystals. Yield 68.8%; mp 190°-193° C. (dec); NMR 
9DMSO-d6) a 1.14 (d, 6H, J- 6 Hz), 1.6-2.2 (m, 4H), 
3.1-4.8 (m, 6H), 7.52 (d, 2H, j-9 Hz), 8.48 (d, 2H, J-9 
Hz); IR (Nujol) 1740, 1725, 1615, 1595, 1520 cm‘‘. 
Anal. calcd for C15H12ClN3O5: C, 51.69; H, 5.96; N, 
11.30; Cl, 9.53. Found: C, 51.52; H, 5.98; N, 11.21; Cl, 
9.55. 
EXAMPLE 9 
Phenyl N-(L-Prolylmethyl)-N-Isopropyl Carbamate 
Hydrochloride 
This compound was prepared using the procedure of 
Example 8 but the product of Example 7 as starting 
material. Yield, 58%; m.p. 207°-208° C. (dec); NMR 
(DMSO-d6) & 1.0-1.4 (m, 6H), 1.7—2.2 (m, 4H), 3.0-3.7 
(m, 2H), 4.1-4.9 (m, 4H), 7.1-7.7 (m, 5H); IR (Nujol) 
1750, 1725, 1600, 1550 cm-1. Anal. Calcd for 
C16H23ClN2O3: C, 58.80; H, 7.09; N, 8.57; Cl, 10.85. 
Found: C, 58.57; H, 7.13; N, '8.54; Cl, 10.92. 
EXAMPLE 10 
p-Nitrophenyl N-(Methy 
Succinyl-L-Alanyl-L-Alanyl-L-Prolymethyl)-N-Iso 
propyl Carbamate 
To a stirred mixture of methy/succinyl-L-alanyl-L 
alanine from example 2 (213 mg, 0.778 mmol) and N 
methyl morpholine (86 ul, 0.778 mmol) in THF (2.5 ml) 
at — 15° to —30° C. was added, dropwise, a solution of 
isobutyl/chloroformate (101 ul, 0.778 mmol) in THF(1 
ml), and the mixture stirred for 30 min at the same tem 
perature. A solution of the product from Example 8, 
(0.779 mmol), N-methyl morpholine (0.778 mmol) and 
bis (trimethylsilyl) acetamide (1 ml in THF (3 ml) was 
then added dropwise to the above mixture at —50° C. 
The reaction mixture obtained was warmed up gradu 
ally stirred at room temperature overnight, diluted with 
CHC13 (10 ml), successively washed with 10% citric 
acid, and 4% NHHCO3 solution and evaporated. The 
resulting oil was puri?ed by column chromatography 
(CHC13 MeOH, 50:1) to give crystals. Yield, 82%; m.p. 
153°-163° C.; NMR (CDC13) & 1.0-1.5 (m, 12H), 
4,643,991 
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1.8-2.4 (m, 4H), 2.4—2.9 (m, 4H), 3.5-4.0 (m, 2H), 3.83 
(s, 3H), 4.2—5.0 (m, 6H), 6.5-7.7 (In, 4H), 8.46 (d, 2H, 
J=7 HZ); IR (Nujol) 3350, 1737, 1720, 1688, 1655, 1645, 
1525 Cm_1. Anal Calcd for C27H37N5010: C, 54.82; H, 
6.30; N, 11.84. Found: C, 54.60; H, 6.34, N, 11.73. 
EXAMPLE 1 l 
Phenyl N-(Methyl 
Succinyl-L-Alanyl-L-Alanyl-L-Prolyl 
Methyl)-N-Isopropyl Carbamate ' 
This compound was prepared using the procedure of 
Example 10 and the product of Example 9 as starting 
material. Yield, 67%; mp. 60°-65° C.; NMR (CDC13) & 
0.7-1.4 (m, 12H), 1.7-2.2 (m, 4H), 2.3-2.8 (m, 4H), 3.77 
(s, 3H), 3.1-3.40 (m, 2H), 4.0-4.8 (m, 6H), 6.1-7.6 (m, 
7H); IR (Film) 3300-3500, 1730 (br), 1645 (br), 1530 (br) 
cm*1. Anal. calcd for Cpl-133N403: C, 59.33; H, 7.01; 
N, 10.25. Found: C, 59.16; H, 7.06; N, 10.17 
EXAMPLE l2 
(N-t-Boc-L-prolyl) chloromethane 
The title compound was prepared in the same manner 
as that of Example 4. (76.3% yield from N-Boc-proline). 
EXAMPLE 13 
N-(N’-t-Boc-L-prolyl)methyl-N-isopropylamine 
To a solution of (N-t-Boc-L-prolyl)chloromethane 
(3.0 g, 0.0121 mol) in ether (40 ml) ‘at 5° C. was added 
isopropylamine (12 ml). The solution was stirred over 
night in an ice bath and allowed to come to room tem 
perature. Precipitated isopropylamine hydrochloride 
was ?ltered off and washed with ether. The ?ltrate was 
evaporated in vacuo to give an oil. The oil was puri?ed 
by column chromatography (silica gel 45 g, solvent 2% 
MeOH-CHCl3) to give 216 g of the product as an oil. 
NMR (&, CDC13), 1.12 (6H, d, J=6 Hz), 1.50 (9H, s), 
1.8-2.2 (4H, m), 2.83 (1H, m), 3.3-3.9 (5H, m), 4.30 (1H, 
m) ppm; IR (Film) 3330 (br), 1690 cm-1. 
EXAMPLE 14 
l-Methyl-S-tetrazolyl thiochloroformate 
A solution of triethylamine (0.647 ml, 4.64 mmol) in 
THF (2 ml) was added dropwise to a mixture of l-meth 
yl-5-mercaptotetrazole (450 mg‘, 3.87 mmol) in the THF 
(5 ml) and 12.5% phosgene in benzene (4.7 ml, 6 mmol) 
at 0°-5° C. The mixture was stirred at 0°—5° C. for 30 
min and at room temperature for 2 h, followed by ?ltra 
tion of the mixture. The ?ltrate obtained was evapo 
rated go give 0.62 g (89.7%) of pale brown crystals of 
the title compound NMR (CDC13) & 4.23 (S, 3H), IR 
(Film) 1770 cm-1. 
EXAMPLE 15 l-Methyl-S-tetrazolyl 
N-(N’-t-Boc-L-prolyl)methyl-N-isopropylthiocarba 
mate 
To a solution of the product of Example 13 (1.95 g, 
-7.2 mmol) and triethylamine (1.30 ml, 9.36 mmol) in 
THF (15 ml) at 5° C. was added a suspension of l-meth 
yl-5-tetrazolyl thiochloroformate from Example 15, 
(1.67 g, 9.36 mmol) in THF(10 m1) over 4 min, and the 
mixture was stirred for 1 hour at 5° C. CHC13. The 
organic layer was dried over anhydrous MgSO4 and 
evaporated in vacuo to give an oil. The oil was puri?ed 
by column chromatography (silica gel 40 g) using 
CHC13 as an eluent to give 1.86 g of the product as an 
oil, 74% yield. The oil was crystallized from ethyl ace 
tate-hexane mp 145°-150° C. NMR (&, CDC13) 1.30 
20 
35 
40 
45 
65 
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(6H, <1, J=6 Hz), 1.46 (91-1, s), 1.11-2.2(411, m), 3.4-3.7 
(2H, m), 4.10 (3H, s), 40-46 (411, m) ppm IR (Film) 
1735, 1685, 1670 cm- 1. Anal. Calcd for C17H2gN6O4S: 
c, 49.50; H, 6.84; N, 20.37. Found: c, 49.65; 11, 6.87; N, 
20.30. 
EXAMPLE l6 
l-Methyl-S-tetrazolyl 
N-(L-prolylmethyD-N-isopropylthio-carbamate 
Hydrochloride 
The title compound was prepared by the same 
method as that of Example 8 (52% yield). 
EXAMPLE l7 
l-Methyl-S-tetrazolyl N-(methyl 
succinyl-L-alany]-L-alanyl-L-prolylmethyl)-N-iso 
propylthiocarbamate 
The title compound was prepared by the same 
method as that of Example 10. The obtained oil was 
crystallized from ethyl acetate-hexane, 21% yield, mp 
ll0°-l13° C. NMR (&, CDC13), 0.9-1.5 (12H, 111), 
1.8-2.2 (4H, m), 2.4-2.8 (4H, 111), 3.5-3.8 (2H, m), 3.76 
(3H, s), 4.10 (3H, s), 4.0-4.9 (6H, m), 6.56 (1H, brd, .1-8 
Hz), 7.20 (1H, brd, J =8 Hz), ppm. IR (Film); 3300, 
1735, 1680-1640, 1520 cm-1. Anal. Calcd. for 
C23H36N3O7S: C, 48.58; H, 6.38; N, 1970. Found: C, 
48.41; H, 6.43; N, 19.58. 
EXAMPLE 18 
N-(N'-t-Boc-L-prolyl)methyl-N-cyclopropylamine 
The title compound was prepared in a similar manner 
to Example 13 and obtained as an oil, 52.4% yield. 
NMR (&, CDC13) 0.33 (4H, m), 1.46 (9H, s), 2.0-2.3 
(6H, m), 3.3-3.9 (4H, m), 4.40 (1H, m) ppm, IR (Film) 
3260, 1720, 1680, 1400, 1160 cm—1. 
EXAMPLE l9 
1-Methyl-5-tetraazolyl 
N-(N’-t-Boc-L-prolyl)methyl-N-cyclopropyl 
thiocarbamate 
The title compound was prepared in a similar manner 
to Example 15 as a powder, 30% yield. m p 144°-148° 
C. NMR (&, CDC13); 1.00 (4H, m), 1.46 (9H, s), 1.7-2.3 
(4H, m), 2.96 (1H, m), 3.53 (2H, m), 4.06 (3H, s), 4.30 
(3H, m) ppm. IR (Film) 1730, 1680, 1480, 1400 cm—l. 
Anal. Calcd. for C|7H26N604S: C, 49.75; H, 6.34; N, 
20.48. Found: C, 49.49; H, 6.39; N, 20.34. 
EXAMPLE 2O 
l-Methyl-S-tetrazolyl 
N-(L-prolylmethyl)-N-cyclopropylthiocarbamate 
Hydrochloride 
The compound of Example 39 (0.82 g, 2 mmol) was 
dissolved in ethyl acetate (30 ml). HCl gas was passed 
through the solution at room temperature for 5 minutes. 
After evaporation of the solvent, the residue was tritu 
rated with ether to give a powder 80% yield, mp 
l44°-148° C. NMR (&, DMSO-d?): 1.00 (4H, m), 
1.5-2.0 (4H, m), 3.20 (3H, m), 4.00 (1H, m), 4.07 (3H, s), 
460 (2H, m) ppm. IR (Nujol) 1725 1670, 1260 cm—1. 
Anal. Calcd. for C12H19ClN6O2S: C, 41.78; H, 5.48; N, 
24.24; S, 9.23. Found: C, 41.60; H, 5.55; N, 24.17; S, 
10.32. 
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EXAMPLE 21 
l-Methyl-S-tetrazolyl N-(methyl 
succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N-cyclo 
propylthiocarbamate 
The title compound was prepared in a manner similar 
to Example 17. The product powder was obtained in 
60.8% yield, mp 107°-l09° C. NMR (&, CDCl3) 1.00 
(4H, m), 1.36 (6H, d, J =6 Hz), 1.8-2.4 (4H, m), 2.63 
(4H, m), 3.0 (1H, m), 3.66 (2H, m), 3.73 (3H, s), 4.08 
(3H, s), 4.3-4.9 (5H, m) ppm. IR (CHC13) 3300-3400, 
1730, 1710, 1680, 1510 cm“. Anal. Calcd. for 
C23H34N307S: C, 48.76; H, 6.05; N, 19.77. Found C, 
48.56; H, 6.07; N, 19.57. 
EXAMPLE 22 
N-(N-t-Boc-L-prolyl)methyl-N-propylamine 
The title compound was prepared in a similar manner 
to Example 13 as an oil, 54% yield. NMR (&, CDCl3) 
0.90 (3H, t, J =7 Hz), 1.43 (9H, s), 1.6-2.3 (6H, m), 2.67 
(2H, t, J=7 Hz), 3.3-3.7 (4H, m), 4.33 (1H, m) ppm. IR 
(Film) 3300, 1710, 1690, 1380 cm-1. 
EXAMPLE 23 
l-Methyl-S-tetrazolyl 
N-(N’-t-Boc-L-prolyl)methy1-N-propyl thiocarbamate 
The title compound was prepared in a similar way to 
Example 15 to give crystals, 23.5% yield. mp l12°-114° 
C. NMR (&, CDC13) 1.00 (3H, t, J =7 Hz), 14.6 (0H, s), 
1.6-2.3 (6H, 111), 32-3.? (4H, m), 4.10 (3H, s), 4.30 (3H, 
m) ppm. IR (Film) 1730, 1680, 1380, 1160 cm-1. Anal. 
Calcd. for C17H2gN6O4S: C, 49.51; H, 6.79; N, 20.38. 
Found: C, 49.23; H, 6.84; N, 20.30. 
EXAMPLE 24 
l-Methyl-S-tetrazolyl 
N-(L-prolylmethyl)-N-propylthio carbamate 
Hydrochloride 
The title compound was prepared in a similar manner 
to Example 20, 84% yield, m p l07°-112° C. NMR (&, 
DMSO-d6) 1.0 (3H, m), 1.2-2.0 (6H, m), 3.0 (2H, m), 
4.07 (3H, s), 4.25-5.0 (5H, 111) ppm. IR (Film) 3350, 
1740, 1680 cm—1. 
EXAMPLE 25 
l-Methyl-S-tetrazolyl N-(methyl 
succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N-propyl 
thiocarbamate 
The title compound was prepared in a similar manner 
to Example 17, mp, 138°-140° C. 22.3% yield. IR (Film) 
3300, 1735, 1650, 1530, 1170 cm“. NMR (&, CDC13) 
1.00 (3H, br, t, J=7 Hz), 1.40 (6H, d, J=7 Hz) 1.2-1.8 
(2H, m), 2.07 (4H, m), 2.66 (4H, m), 3.50 (2H, m), 3.70 
(3H, s), 4.10 (3H, s), 4.2-5.0 (5H, m), 6.9 (1H, m), 7.4 
(1H, m) ppm. Anal. calcd. for C23H36NgO7: C, 48.58; H, 
6.38; N, 19.71. Found: C, 48.37; H, 6.38; N, 19.64. 
EXAMPLE 26 
p-Nitrophenyl 
N-(N'-t-Boc-L-prolyl)methyl-N-propylcarbamate 
The title compound was prepared in the same way as 
that of Example 6 to recover an oil, 51.7% yield. NMR 
(&, CDC13) 0.93 (3H, br, t, J =7.5 Hz), 1.46 (9H, s), 
1.5-2.5 (6H, m), 3.50 (4H, m), 4.30 (3H, m), 7.40 (2H, 
12 
m), 8.30 (21-1, 111) ppm. IR (Film) 1740, 1700, 1670, 1610 
cm- 1. 
EXAMPLE 27 
5 P-Nitrophenyl N-(L-prolylmethyl)-N-propylcarbamate 
20 
25 
30 
40 
45 
50 
60 
Hydrochloride 
The title compound was prepared in the same manner 
as previous Example 8. The compound of Example 26 
(0.72 g, 1.65 mmol) was dissolved in a mixture of formic 
acid (10 ml) and 1N HCl in THF (10 ml). The solution 
was stirred at room temperature for 3 hours. Evapora 
tion of the solvent gave a residue which was triturated 
with ether to give a powder. The powder was collected 
and washed with ether to give 0.49 g of the product. 
79.8% yield. m p 155°-160° C. NMR (&, DMSO-d6) 0.9 
(3H, br, t, J =9 Hz), 1.1-2.2 (6H, m), 3.0-3.7 (4H, m), 
4.3-4.8 (3H, m), 7.46 (2H, d, J=9 Hz), 8.37 (2H, d, J=9 
Hz) ppm. IR (Nujol) 3400, 1720, 1610, 1590, 1520 cm* 1. 
EXAMPLE 28 
P-Nitrophenyl N-(methyl 
succinyl-L-alanyl-L-alanyl-L-prolylmethyl) 
N-propylcarbamate 
The title compound was prepared in the same manner 
as that of Example 10. 20.1% yield, m p l58°-l61° C. 
NMR (&, CDC13) 0.96 (3H, m), 1.36 (6H, br, (1, J :65 
Hz), 1.5-2.3 (6H, m), 2.63 (4H, br, s), 3.2-4.0 (4H, m), 
3.70 (3H, 5), 4.2-50 (5H, m), 7.0 (1H, br, 11, J :65 Hz), 
7.1-7.63H, m), 8.30 (2H, br, d, J=9 Hz) ppm. IR (?lm) 
3320, 1740, 1650, 1580, 1550 cm-l. 
EXAMPLE 29 
P-Nitrophenyl 
N-(N'-t-Boc-L-prolyl)methyl-N-cyclopropylcarbamate 
The title compound was prepared in the same way as 
that of Example 6 as an oil. 45% yield, NMR (&, 
CDC13) 0.86 (4H, m), 1.50 (9H, s), 1.7-2.5 (4H, m), 3.0 
(1H, m), 3.56 (2H, m), 4.40 (3H, m), 7.43 (2H, brd, J =9 
Hz), 8.33 (2H, br, d, J =9 Hz) ppm IR (?lm) 1740, 1720, 
1700, 1610, 1590, 1390, 1210 cut-1. 
EXAMPLE 30 
P-Nitrophenyl 
N-(L-prolylmethyl)-N-cyclopropylcarbamate 
hydrochloride) 
HCl gas was passed through a solution of the product 
of Example 29 (1.3 g, 3.0 mmol) in ether (40 ml) for 6 
min at room temperature. Precipitated amine salts were 
collected and washed with ether to give the product 
(0.7 g), 63% yield. m p 150° C. (dec). NMR (&, CDC13), 
0.81 (4H, m), 1.7-2.3 (4H, m), 2.90 (1H, m) 3.23 (2H, m), 
4.60 (3H, m), 7.46 (2H, brd, J =9 Hz), 8.36 (2H, d, J =9 
Hz). Anal. Calcd for C16H20C1N3O5: C, 51.96; H, 5.44; 
N, 11.36. Found, C, 51.72; H, 5.48; N, 11.30. 
EXAMPLE 31 
P-Nitrophenyl N-(methyl 
succinyl-L-alanyl-L-analyl-L-proly1methyl)-N-cyclo 
propylcarbamate 
The title compound was prepared in the same manner 
as Example 10 and was obtained as a powder, 61% 
yield. m p 154°-158° C. IR (?lm) 3340, 1740, 1690, 1655, 
1640, 1590, 1520 cmrl. NMR (&, CDC13) 0.83 (4H, m), 
1.40 (6H, d, J =7 Hz), 1.8-2.3 (4H, m), 2.60 (4H, m), 3.0 
(1H, m), 3.60 (2H, m), 3.70 (3H, s), 4.2-5.0 (5H, m), 6.38 
(1H, br, d, J=8 Hz), 7.03 (1H, br, t, J=8 Hz), 7.36 (2H, 
4,643,991 
13 
d, J =9 Hz), 8.30 (2H, d, J =9 Hz). Anal. Calcd. for 
C27H35N5O10: C, 55.00, H, 5.98; N, 11.88. Found C, 
54.80; H, 5.99; N, 11.76. 
EXAMPLE 32 
N-(N'-t-Boc-L-prolyl)methyl-N-butylamine 
To a solution of the product of Example 12 (2.8 g, 
0.0113 mol) in ether (70 ml) at 5° C. was added n-butyla 
mine (8.2 ml 0.0831 mol). The solution was stirred at 5° 
C. for 5 hours. Precipitated salts were ?ltered and 
washed with ether. The ?ltrate was evaporated in 
vacuo to give an oil. The oil was purified by column 
chromatography (silica gel 15 g, solvent 2% MeOH 
CHC13) to give 3.2 g of the product as an oil. IR (Film) 
3300, 1690, 1380 cm-1. NMR (&, CDC13) 1.0 (3H, m), 
1.50 (9H, s), 1.2-1.8 (4H, m), 1.8-2.2 (4H, m), 2.60 (2H, 
m), 3.1-3.9 (5H, m), 4.33 (1H, m). 
EXAMPLE 33 
l-Methyl-S-tetrazolyl 
N-(N'-t-Boc-L-proly1)methyl-N-butyl thiocarbamate 
The title compound was prepared in a manner similar 
to Example 15, 35.1% yield, mp 125°-128° C. IR 
(Nujol), 1735, 1670, 1170, 1120 cm~1, NMR (&, 
CDC13), 0.96 (3H, brt, J =5 Hz), 1.46 (9H, s), 1.2-1.8 
(4H, m), 2.0 (41-1, m), 3.2-3.7 (4H, m), 4.07 (3H, s), 
4.2-4.6 (3H, m) ppm. Anal. Calcd. for C13H30N6O4S. C, 
50.69; H, 7.09; N, 19.70. Found: C, 50.75; H, 7.14; N, 
19.66. 
EXAMPLE 34 
l-Methyl-S-tetrazolyl 
N-(L-prolylmethyl)-N-butylthiolcarbamate 
Hydrochloride 
The title compound was prepared in a similar manner 
to Example 20, 91.9% yield, m p 120°-129° C. IR 
(Nujol) 3350, 1735, 1665,1560, 1200 cm". NMR (&, 
DMSO-d6) 0.96 (3H, m), 1.2-2.3 (8H, m), 3.0-3.6 (4H, 
m), 4.06 (3H, s), 4.4-5.0 (3H, m). Anal. Cacld. for 
C13H23CIN6O2S; C, 43.03; H, 6.39. Found C, 43.10; H, 
6.62. . 
EXAMPLE 35 
l-Methyl-S-tetrazolyl N-(methyl 
succinyl-L-alanyl-L-alanyl-L-prolymethyl)-N-butylthi 
ocarbamate 
To a solution of the product of Example 2, (0.428 g, 
0.00173 mol) and N-methyl morpholine (0.175 g, 
0.00173 mol) in THF (3 ml) at —15° C. was added a 
solution of isobutyl chloroformate (0.236 g, 0.00173 
mol) in THF (1.6 ml). The mixture was stirred at — 15° 
C. for 10 minutes. To the mixture at — 15° C. was added 
a solution of the product of Example 34, (0.57 g, 0.00157 
mol) and N-methyl-morpholine (0.159 g) in CH3CN (5 
ml). The mixture was stirred at 5° C. for 1.5 hours and 
stored at 5° C. overnight. The reaction mixture was 
diluted with CHC13, washed with 10% aq. citric acid, 
water and saturated NaCl solution, and dried over an 
hydrous MgSO4. Evaporation of the solvents gave an 
oily residue which was puri?ed by column chromatog 
raphy (silica gel 16 g, solvent: 2% MeOH-CHCl3) to 
give 0.37 g of the product as an oil. The oil was crystal 
lized from ethyl acetate-hexane to give 0.27 g of the 
product, mp 140°-'-l45° C. 29.5% yield. IR (Nujol) 3340, 
1730, 1690, 1655, 1630, 1535 cm—1. NMR (8: CDC13) 
1.00 (3H, m), 1.2-1.8 (4H, m), 1.37 (6H, d, J =7 Hz), 2.07 
(4H, m), 2.63 (4H, m), 3.3-3.9 (4H, m), 3.73 (3H, s), 4.10 
35 
50 
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(3H, s), 4.2—5.0 (5H, m), 6.50 (1H, b1‘, d, J =7 Hz), 7.10 
(1H, br, d, J =7 Hz) ppm. Anal Calcd. for 
C24H33N307S: C, 49.47; H, 6.57; N, 19.23. F0und=C, 
49.52; H, 6.58; N, 19.08. 
EXAMPLE 36 
l-Phenyl-S-tetrazolyl 
N-(N'-t-Boc-L-prolyl)methyl-N-isopropylthiocarba 
mate 
The title compound was prepared in a similar manner 
as that of Example 15 as an oil, 73.8% yield. IR (Film) 
1735, 1690, 1590, 1495, 1400 cm-L NMR (&, CDClg), 
1.17 (6H, d, J =7 Hz), 1.47 (9H, s), 1.95 (4H, m), 3.46 
(2H, m), 3.9-4.6 (4H, m), 7.70 (5H, s). 
EXAMPLE 37 
l-Phenyl-S-tetrazolyl 
N-(L-prolylmethyl)-N-isopropylthiocarbamate 
Hydrochloride 
The title compound was prepared in a similar manner 
‘to Example 20 as an amorphous powder 46.2% yield. 
IR (Nujol) 3400, 1760, 1730, 1670, 1590 cm-1. NMR 
(&, DMSO-dg) 1.13 (6H, m), 2.0(41-1, m), 3.30 (2H, m), 
3.8-4.8 (4H, m), 7.7—8.0 (5H, m) ppm. 
EXAMPLE 38 
l-Phenyl-S-tetrazolyl N-(methyl 
succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N-iso 
propylthiolcarbamate 
The title compound was prepared in a similar manner 
to Example 35, 44.0% yield, mp 103°—l08° C. IR 
(Nujol) 3340, 1735, 1680, 1655, 1530 cm-1. NMR (&, 
CDC13), 0.8-1.7 (12H, m), 2.03 (4H, m), 2.60 (4H, m), 
3.66 (2H, m), 7.60 (5H, s) ppm. Mal. Calcd. for 
C23H38N307S: C, 53.32; H, 6.07; N, 17.77. Found: C, 
53.17; L H, 6.15; N, 17.68. 
EXAMPLE 39 
N-(N'-t-Boc-L-prolyl)methyl-N~allylamine 
The title compound was prepared in a similar manner 
as that of Example 13 as an oil, 55.9% yield IR (Film) 
3320, 1700, 1400, 1160 cm-1. NMR (&, CDC13) 1.46 ' 
(9H, s), 2.00 (4H, m), 3.30 (2H, d, J=5.5 Hz), 3.4-3.s 
(4H, m), 4.40 (1H, m), 5.044 (2H, 111), 5.5-6.3 (1H, m) 
EXAMPLE 40 
l-Methyl-S-tetrazolyl 
N-(N’-t-Boc-L-prolyl)methyl-N-allylthiocarbamate 
The tile compound was prepared in a similar manner 
as that of Example 15, as a powder, 39.5% yield, mp 
124°—126° C. IR (CHC13) 1735, 1685, 1160 cm-1. NMR 
(&, CDCl3): 1.47 (9H, s), 2.0 (4H, m), 3.50 (2H, m), 4.10 
(3H, s), 4.0-4.6 (5H, 111), 5.1-5.5 (2H, m), 5.6-6.4 (1H, m) 
ppm; Anal. Calcd for C17H26N6O4S C, 49.74, H, 6.38; 
N, 20.47 Found: C, 49.50; H, 6.45; N, 20.37. 
EXAMPLE 41 
il-Methyl-S-tetrazolyl - 
N-(L-proly1methyl)-N-allylthiocarbamate 
Hydrochloride 
The title compound was prepared in a similar manner 
as Example 20 as a powder, 93.8% yield, NMR (&, 
DMSO-D6), 1.90 (4H, m), 3.20 (2H, m), 4.07 (3H, s), 
3.9-4.9 (5H, m), 5.0-5.6 (2H, m), 5.7-6.3 (1H, m) ppm. 
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EXAMPLE 42 
l-Methyl-S-tetrazolyl N-(methyl 
succinyl-L-alanyl-L-alany1-L-prolylmethyl)-N-allylthi 
ocarbamate 
The title compound was prepared in a similar manner 
as Example 17 as a powder. 24.3% yield, mp 143°—l45° 
C. IR (Film) 3340, 1735, 1660, 1530, 1450 cm—1. NMR 
(&, CDC13), 1.40 (6H, d, J =I-Iz), 2.10 (4H, m), 2.66 (4H, 
m), 3.73 (3H, s), 3.6-3.8 (2H, m), 4.10 (3H, s), 4.1-5.0 
(7H, m), 5.1-5.6 (2H, m), 5.6-6.3 (1H, m), 6.8 (1H, br, d, 
J =7 Hz), 7.20 (1H, 111) ppm. Anal. Calc. for 
C23H34N307S: C, 48.75; H, 6.05; N, 19.78. Found C, 
48.51, H, 6.08, N, 19.68. 
EXAMPLE 43 
N-(N’-t-Boc-L-prolyl)methyl-N-(2-methyl)proplya 
mine 
The title compound was prepared in a similar manner 
as Example 13 as an oil, 69.75 yield. NMR (&, CDCl3), 
0.93 (6H, d, J=6 Hz), 1.46 (9H, s), 1.3-1.6 (1H, m), 2.0 
(4H, m), 2.43 (2H, m), 3.3-4.3 (4H, m), 4.40 (1H, m) 
ppm. IR (Film) 3340, 1700, 1470, 1400 cm"1. 
EXAMPLE 44 
P-Nitrophenyl 
~ N-(N’-t-Boc-L-prolyl)methyl-N-(2-methyl)lpropylcar 
bamate 
The title compound was prepared in a similar manner 
as Example 6 as an oil, 93% yield. IR (Film) 1730, 1615, 
1595, 1525 cm-1. NMR (&, CDCL3), 0.96 (6H, d, J =6 
Hz), 1.43 (9H, s), 1.3-1.6 (1H, m), 2.0 (4H, m), 3.1-3.8 
(4H, m), 4.1-4.6 (3H, m), 7.3 (2H, br, d, J =9 Hz), 8.33 
(2H, d, J =8 Hz) ppm. 
EXAMPLE 45 
P-Nitrophenyl N-(L-prolylmethyD-N-(2-methyl) 
propylcarbamate Hydrochloride 
The title compound was prepared in a similar manner 
as that of Example 30 as a powder, 47% yield, mp 
135°—149° C. IR (Nujol) 3500, 1740, 1710, 1615, 1595 
cm-1. NMR (&, DMSO-d6), 0.95 (6H, d, .1 =6 Hz), 
1.3—2.2 (7H, m), 3.0-3.6 (4H, m), 4.1-4.8 (3H, m), 7.43 
(2H, br, d, dd, J =2, 9 Hz), 8.36 (2H, d, J =9 Hz) ppm. 
EXAMPLE 46 
p-Nitrophenyl N-(methyl 
succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N-(2 
methyl)propylcarbamate 
The title compound was prepared in a similar manner 
as that of Example 10 as a powder, 57.7% yield mp 
177°-179° C. IR (Nujol) 3350, 1735, 1695, 1660, 1635, 
1595 cm—1. NMR (&, CDCl3): 0.96 (6H, d, J =7.5 Hz), 
;b 1.35 (6H, d, J =7 hz), 1.5-2.0 (1H, m), ‘2.0 (4H, m), 
2.60 (4H, m), 3.30 (2H, m), 3.70 (3H, s), 3.70 (2H, m), 
4.1-5.0 (5H, m), 6.50 (1H, br, d, J=7 Hz), 7.10 (1H, m), 
7.30 (2H, d, J=9 Hz), 8.30 (2H, d, J=9 Hz) ppm. Anal. 
Calcd. for C23H39N5010: C, 55.53; H, 6.44; N, 11.57. 
Found: c, 55.29; H, 6.55; N, 11.46. 
EXAMPLE 47 
N-(N'-t-Boc-L-prolyl)methyl-N-phenylmethylamine 
The title compound was prepared in a similar manner 
as that of Example 13 as an oil, 63.5% yield. IR (Film) 
3310, 1700, 1605, 1585, 1400 cm-‘l. NMR (&, CDC13), 
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1.43 (9H, s), 1.96 (4H, m), 3.3-4.0(61-1, m), 4.33 (1H, m), 
7.36 (5H, s) ppm. 
EXAMPLE 48 
P-Nitrophenyl 
N-(N’-t-Boc-L-prolyl)methyl-N-phenylmethylcarba 
mate 
The title compound was prepared in a similar manner 
as that of Example 6 as an oil, 56% yield. IR (CHC13): 
1730, 1690, 1615, 1595, 1525 cm—1. NMR (&, CDC13): 
1.43 (9H, s), 1.7-2.3 (4H, m), 3.50 (2H, m), 4.0-5.0 (5H, 
m), 7.37 (7H, m), 8.33 (2H, d, J =0 Hz) ppm. 
EXAMPLE 49 
P-Nitrophenyl 
N-(L-prolylmethyl)-N-phenylmethylcarbamate 
Hydrochloride 
The title compound was prepared in a similar manner 
as that of Example 30 was a powder. 38.4% yield mp 
136°-142° C. IR (Nujol) 3400, 1730, 1670, 1590 cm-1. 
NMR (&, DMSO-d6), 2.00 (4H, m), 3.3 (2H, m), 4.2-5.0 
(5H, m), 7.3-7.4 (7H, m), 8.33 (2H, d, J =9 Hz) ppm. 
EXAMPLE 50 
P-Nitrophenyl N-(methyl 
succinyl-L-alanyl-L-alanyl-L~prolylmethyD-N-phenyl 
methylcarbamate 
The title compound was prepared in a similar manner 
as that of Example 10 as a powder, 39.6% yield mp 
14l°-l43° C. IR (Nujol) 3340, 1730, 1690, 1660, 1630, 
1520 cm—1. NMR (&, CDCl3), 1.2-1.8 (6H, m), 2.00 
(4H, m), 3.70 (2H, m), 4.2—5.0 (7H, m), 6.46 (1H, m), 
3.70 (3H, s), 3.70 (2H, m), 4.2-5.0 (7H, m). 6.46 (1H, br, 
d, J =7 Hz), 7.10 (1H, br, d, J =7 Hz), 7.3-7.6 (7H, m), 
8.33 (2H, d, J =9 Hz) ppm. Anal. Calcd. for 
C31H37N5O10. C, 58.21; H, 5.79; N, 10.95. Found: C, 
57.97; H, 5.86; N, 10.89. 
EXAMPLE 51 
N (N'-t-Boc-L-prolyl)methyl-N-cyclohexylamine 
The title compound was prepared in a similar manner 
as that of Example 13 as an oil, 43.9% yield. IR (Film) 
3320, 1690, 1390 cm-1. NMR (&, CDC13), 0.9-2.5 (15H, 
m), 1.47 (9H, s), 3.3-3.9 (4H, m), 4.33 (1H, in), ppm. 
EXAMPLE 52 
P-Nitrophenyl 
N-(N '-t-Boc-L-pro1yl)methyl-N-cyclohexylcarbamate) 
The title compound was prepared in a similar manner 
as that of Example 6 as an oil, 80.1% yield IR (Film) 
1725, 1690, 1612, 1590, 1520 cm—1. NMR (&, CDC13), 
0.9-2.3 (14H, m), 1.47 (9H, s), 3.3-4.0 (3H, m), 4.1-4.6 
(3H, m), 7.13 (2H, dd, J=3.5, 9 Hz), 8.30 (2H, d, J=9 
HZ) PPm- - 
EXAMPLE 53 
P-Nitrophenyl 
N -(L-prolylmethyl)-N-cyclohexylcarbamate 
Hydrochloride 
The title compound was prepared in a similar manner 
as that of Example 30 as a powder, 77.3% yield, mp 
l46°-158° C. IR (Nujol) 1720, 1612, 1595, 1515 cm-l. 
NMR (&, DMSO-dg) 1.1-2.6 (14H, m), 3.3-4.9 (6H, m), 
1.47 (2H, dd, J =3.5, 9 Hz), 8.43 (2H, d, J =9 Hz) ppm. 
4,643,991 - 
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EXAMPLE 54 
P-Nitrophenyl N-(methyl 
succinyl-L-alanyl-L-alanyl~L-prolylmethyl)-N 
cyclohexylcarbamate 
The title compound was prepared in a similar manner 
as that of Example 10 as a powder, 62.9% yield mp 
l50°-154° C. IR(Nujol) 3345, 1735, 1690, 1655, 1595 
cm~1. NMR(&, CDC13), 1.2-2.4(14H, m), l.40(6H, d, 
J =7.5 Hz), 2.66(4H, m), 3.73(3H, s), 3.5-5.0(8H, m), 6.4 
(1H, m), 7.0(1H, m), 7.4(2H, d, J =9 Hz), 8.33(2H, d, 
J'=9 HZ). Anal. Calcd. for C30H4|N5010: C, 57.05; H, 
6.49; N, 11.09. Found: C, 56.87; H, 6.54; N, 11.00 
EXAMPLE 55 
Penta?uorophenyl-N-(N'-t-Boc-L-prolyl 
methyl~N-isopropylcarbamate 
This compound was prepared according to the proce 
dure described in Example 6; NMR (CDC13) & 1.1-1.4 
(m, 6H), 1.48 (S, 9H), 1.9-2.3 (m, 4H, 3.4-3.8 (m, 2H), 
4.2-4.7 (m, 4H); IR (Film) 1750, 1690, 1515 cm—l-'. 
EXAMPLE 56 
Pentalluorophenyl-N-(L-prolylmethyl)-N-isopropyl 
carbamate hydrochloride 
This compound was prepared according to the proce 
dure described in Example 8: mp l89°-l90° C.; NMR 
(DMSO-d@) & 1.0—1.3 (m, 6H), 1.7-2.3 (m, 4H), 3.1-3.5 
(m, 2H), 4.0-4.9 (M, 4H); IR (Nujol) 1750, 1515 cmrl. 
Anal. calcd. for C|6H1gN2ClF5O3: C, 46.11, H, 4.35; N, 
6.72, Cl, 8.50. Found: C, 45.94; H, 4.38; N, 6.66; Cl, 8.67. 
EXAMPLE 57 
Penta?uorophenyl N-(methyl 
succinyl-L-analyl-L-alanyl-L-prolymethyl)-N-isopro 
pyl-carbamate 
This compound was prepared according to the proce 
dure described in Example 10: yield, 44%; mp 
l52°—l54° C.; NRM (CDC13) & 1.0-1.5 (m, 12H), 
1.8-2.3 (m, 4H), 2.5-2.8 (m, 4H), 3.4-4.0 (m, 2H), 3.75 
(S, 3H), 4.0-5.0 (m, 6H), 6.2-7.4 (br, 2H), IR (Nujol) 
3350, 1765, 1740, 1690, 1660, 1640, 1520 cm—l. Anal. 
calcd for C27H33N4F403: C, 50.94, H, 5.22; N, 8.80. 
Found: C, 50.85; H, 5.26; N, 8.78. 
EXAMPLE 58 
Hepta?uorobutyl 
N-(N'-t-Boc-L-prolyl)methyl-N-isopropyl carbamate 
This compound was prepared following the same 
procedure as in Example 6: NMR (CDCl3) & 1.13 (d, 
6H, J-7 Hz), 1.49 (S, 9H), 1.8-2.2 (m, 4H), 3.4-3.7 (m, 
2H), 4.0-5.0 (m, 6H); IR (Film) 1690-1740 cmrl. 
EXAMPLE 59 
Heptafluorobutyl N-(L-prolylmethyl)-N-isopropyl 
carbamate hydrochloride 
This compound was prepared following the proce 
dure in Example 8; mp l49°-150° C.; NMR (DMSO-d6) 
& 1.11 (d, 6H, J-7 Hz), 1.7-2.3 (m, 4H), 3.0-3.4 (m, 2H), 
3.9-5.2 (m, 4H), 4.40 (S, 2H), 9.7 (hr, 2H); IR(Nujol) 
3410, 1745, 1710 cm-1. Anal. calcd for 
C14H20N2ClF7O3: C; 38.86; H, 4.66; N, 6.47; CI, 8.19. 
Found: C, 38.58; H, 4.68; N, 6.43; Cl, 8.20. 
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EXAMPLE 60 
Heptalluorobutyl N-(methyl 
succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N-iso 
propylcarbamate 
This compound was prepared following the proce 
dure in Example 10: Yield, 43%; mp l65°-166° C.; 
NMR (CDC13) & 1.16 (d, 6H, J=7 Hz), 1.38 (d, 6H, J-7 
Hz), 1.9-2.3 (m, 4H), 2.5-2.8 (m, 4H), 3.75 (S, 3H), 
3.6-4.0 (m, 2H), 4.21 (S, 2H), 4.0-5.0 (m, 6H), 6.46 (d, 
1H, J=7 Hz), 7.08 (d, 1H, J=7 Hz); IR (nujol) 3350, 
1735, 1690, 1655, 1640, 1525 cm-1. Anal. calcd. for 
C25H35N4F7Og: C, 46.01; H, 5.41; N, 8.59. Found: C, 
45.89; H, 5.42; N, 8.54. 
EXAMPLE 61 
S-Benzyl 
N-(N’-t-Boc-L-prolyl)methyl-N-isopropylthiocarba 
mate 
This compound was prepared according to the proce 
dure described in Example 6 starting with S-benzyl 
chlorothioformate (J. J. Willard and E. Pacsu, J. Am. 
Chem. Soc., 82, 4317 (1960): NMR (CDC13) & 1.18 (d, 
6H, J=7 Hz), 1.50 (s, 9H), 1.s-2.4 (m, 4H), 34-31; (m, 
2H, 4.26 (S, 2H, 4.2-4.6 (m, 4H), 7.45 (S, 5H); IF (Film) 
1740, 1690, 1640 crn-l. 
EXAMPLE 62 
S-Benzyl 
N-(L-prolylmethyl)-N-isopropylthiocarbamate 
hydrochloride 
This compound was prepared according to the proce- ' 
dure described in Example 8: mp l93°-l94° C.; NMR 
(DMSO-d(,) & 1.10 (d, 6H, J =7 Hz), 1.6-2.3 (m, 4H), 
3.0—3.5 (m, 2H), 4.6 (S, 2H), 4.46 (S, 2H), 4.2-4.8 (m, 
2H), 7.41 (S, 5H), 9.7 (hr, 2H), IR (Nujol) 1745, 1635, 
1545 cm-1. 
EXAMPLE 63 
S-Benzyl N-(Methyl suc'cinyl 
-L-alanyl~L-alanyl-L-prolylmethyl)-N-isopropylthi 
ocarbamate 
This compound was prepared according to the proce 
dure described in Example 10: yield, 41%; mp 
125°-127° C.; NMR (CDC13) & 1.0-1.5 (m, 12H), 
1.7-2.3 (m, 4H), 2.4-2.8 (m, 4H), 3.4-3.9 (m, 2H), 3.80 
(S, 3H)<4.0-4.9 (m, 9H), 7.50 (S, 5H): IR (Nujol) 3360, 
‘1735, 1680, 1655, 1640, 1530 cm-‘l. Anal. calcd. for 
C28H4ON4O7S: (C, 58.23; H, 6.99, N, 9.71, S, 5.56 
Found: C, 58.23, H, 7.00, N, 9.69, S, 5.55. 
EXAMPLE 64 
N-(N'-t-Boc-L-prolyl)methyl-N-methylamine 
Sodium iodide (635 mg, 4.23 mmol) and 40% me 
thylaine aqueous solution (6.9 ml, 80.6 mmol) were 
added to an ice-cooled solution of product from Exam 
ple 4 (1.0 g, 4.03 mmol) in ethanol (10 ml). The mixture 
was shaken in a steel bomb at 65° C. for 12 h and the 
solvent evaporated. Saturated solutions of NaHCO3 (5 
ml) and NaCl (5 ml) were added to the residual mixture. 
The resulting mixture was extracted into ether, evapo 
rated and puri?ed by silica gel column chromatography 
(CHCl3: CH3OH, 50:1) to give 0.29 g (29.7%) of the 
title compound. NMR (CDC13) & 1.40 (s, 9H), 1.7-2.1 
(m, 4H), 2.40 (s, 3H), 3.3-3.7 (m, 4H), 4.1-4.5 (m, 1H), 
IR (Film) 3340 (br), 1695 (br) c-l. 
4,643,991 
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EXAMPLE 65 
p-Nitrophenyl 
N-(N-t-Boc-L-prolylmethyD-N-methylcarbamate 
This compound was prepared in a manner similar to 
that for Example 6: yield 52%, NMR (CDC13) & 1.49 (s, 
9H), 1.8-2.2 (m, 4H), 3.09-3.21 (br. s, 3H), 3.4-3.8 (m, 
2H), 4.3-4.6 (m, 3H), 7.2-7.0 (m, 2H), 8.2-8.5 (m, 2H), 
IR (Film) 1740-1670, 1615, 1590, 1520, 1497 cm-l. 
EXAMPLE 66 
p-Nitrophenyl N-(L-prolylmethyl)-N-methylcarbamate 
hydrochloride 
This compound was prepared using the procedure of 
Example 8: yield 74%; mp l77°-18l° (dec); NMR 
(DMSO-d"’) & 1.7-2.3 (m, 4H), 2.9-3.7 (m, 5H), 4.4-4.8 
(m, 3H), 7.3-7.7 (m, 2H), 8.2-8.5 (m, 2H); IR (Nujol) 
3530, 3450, 1735, 1720, 1612, 1592, 1550, 1515 cm—1. 
EXAMPLE 67 
p-Nitropheny N-(methyl 
succinyl-L-alanyl-L-alanyl-L-prolymethyl)-N-methyl 
carbamate 
This compound was prepared using the procedure of 
Example 10: yield, 41%, mp l05°-l10° C., NMR 
(CDCl3) & 1.1-1.5 (m, 6H), 1.8-2.2 (m, 4H), 2.4-2.8 (m, 
4H), 3.0-3.4 (m, 3H),‘3.5-4.0 (m, 2H, 3.73 (s, 3H), 
4.2-5.0 (m, 5H), 6.1-6.5 (m, 1H), 7.2-7.7 (m, 3H), 
8.1-8.6 (m, 2H); IR (CHC13) 3300, 1735, 1640, 1520 
cm-1. Anal. Calcd. for C25H33N5O10: C, 53.28; H, 5.90; 
N, 12.43 Found: C, 53.53; H, 5.96; N, 12.36. 
EXAMPLE 68 
N-(N’-t-Boc-L-prolyl)methyl-N-t-butylamine 
This compound was prepared following the same 
procedure as in Example 5: yield, 51%, NMR (CDC13) 
& 1.12 (S, 9H), 1.47 (S, 9H), 1.8-2.2 (m, 4H), 3.5-3.8 (m, 
2H), 3.74 (S, 2H), 4.4-4.6 (m, 1H), IR (Film) 3320, 1710, 
1690 cm-l. 
EXAMPLE 69 
p-Nitrophenyl N-(N’-t-Boc-L-prolyl 
methyl)-N-t-butylcarbamate 
This compound was prepared using the procedure of 
Example 6: yellow oil, yield, 49%, NMR (CDC13) & 
1.48 (S, 9H), 1.51 (s, 9H), 1.7-2.2 (m, 4H), 3.4-3.7 (m, 
2H), 4.4-4.7 (m, 3H), 7.2-7.4 (m, 2H), 8.1-8.4 (m, 2H); 
IR (Film) 1740, 1690 (br), 1615, 1593 c-l. 
EXAMPLE 70 
p-Nitrophenyl N-(L-prolymethyl)-N-t-butylcarbamate 
hydrochloride 
This compound was prepared using the procedure of 
Example 8: brown powder; yield, 61%; mp 85°-90° C. 
(dec); NMR (DMSO-d6) & 1.41 (S, 9H), 1.7-2.2 (m, 
4H), 2.8-3.5 (m, 2H), 4.0-4.9 (m, 3H), 6.9-7.5 (m, 2H), 
8.0-8.4 (m, 2H). 
EXAMPLE 71 
p-Nitrophenyl N-(Methyl 
succinyl-L-alanyl-L-alanyl-L-prolylmethyl-N-t-butyl 
carbamate 
This compound was prepared using the procedure of 
Example 10: colorless crystals; yield, 16%; mp 
1.8-2.3 (m 4H), 2.5-3.0 (m, 4H), 3.6-4.1 (m, 5H), 4.4-5.0 
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9 m, 5H), 6.2-6.7 (m, 1H), 6.9—7.7 (m, 3H), 8.0-8.6 (m, 
2H); IR (CHC13) 3300, 1735, 1640, 1590, 1520 cm-1. 
Anal. Calcd. for CHI-139015010: C, 55.53; H, 6.49; N, 
11.56. Found: C, 55.42; H, 6.54; N, 11.51. 
EXAMPLE 72 
N-(N'-t-Boc-L-prolyl)methyl-N-isopropyl-2-thioxo-3 
thiazolidinecarboxamide 
To a solution of N-(N'-t-Boc-L-prolyl)methyl-N-iso 
propylamine (1.7 g, 6.3 mmol) and Et3N (1.09 m], 7.8 
mmol) in THE (20 ml) at 5° C. was added dropwise a 
solution of Compound (88) (1.12 g, 6.2 mmol) in THF 
(20 ml) for 3 min. The solution was stirred at 5° C. for 
45 min and at r.t. for 2 hr. The precipitate was ?ltered 
off and the ?ltrate was evaporated in vacuo to give an 
oil. The oil was puri?ed by column chromatography 
(silica gel 30 g) using 4% ethyl acetate in CHZCIZ as an 
eluting solvent to give 1.3 g of product as an oil 50.5% 
yield. IR(CHC13): 0.9-1.5 (6H, m), 1.46 (9H, S), 1.8-2.2 
(4H, m), 3.1-3.9 (4H, m), 3.9-5.0 (6H, m). 
EXAMPLE 73 
N-(L-Prolylmethyl)-N-isopropyl-2-thioxo-3 
thiazolidinecarboxamie Hydrochloride 
HCl gas was passed through a solution of the com 
pound of Example 72 (1.10 g, 2.60 mmol) in ethyl ace 
tate (30 ml) at r.t. for 5 min. The solution was allowed 
to stand at r.t. for 20 min. The solution was evaporated 
in vacuo to give an oil residue which was triturated 
with ether to give a hydroscopic powder (0.70 g) of 
product 883% yield, IR (CDC13): 3400, 1735, 1690, 
1435 cm-l. NRM (&, DMSO-d6): 0.9-1.3 (6H, m), 
1.8-21. (4H, m), 3.0-4.7 (12H, m). 
EXAMPLE 74 
N-(Methyl - 
succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N-isopro 
pyl-2-thioxo-3-thiazolidinecarboxamide 
To a solution of methyl succinyl-L-alanyl-L-alanine 
(0.38 g, 1.38 mmol) and N-methylmorpholine (0.18 ml, 
1.38 mmol) in acetonitrile (12 ml) at - 15° C. was added 
a solution of isobutyl chloroformate (0.23 ml, 1.38 
mmol) in acetonitrile (5 ml). The mixture was stirred at 
—15° C. for 10 min. To the mixture at —15° C. was 
added a suspension of the compound of Example 73 (0.5 
g, 1.43 mmol) and N-methylmorpholine (0.18 ml, 1.64 
mmol) in acetonitrile (14 ml). The mixture was stirred at 
- 15° C. for 45 min and then at r.t. for 2 hr. The precipi 
tate was ?ltered off and the ?ltrate was diluted with 
10% aqueous citric acid and CH2Cl1. The organic layer 
was separated, dried over anhydrous MgSO4, and evap 
orated in vacuo to give an oil. The oil was puri?ed by 
column chromatography (silica gel 30 g) using 2% ethyl 
acetate in CH2C12 as an eluting solvent. The oil obtained 
was triturated with ether to give a powder of the com 
pound (0.35 g)., 44.3% yield. mp. IR (CHCl3): 3300, 
1730, 1680, 1640, 1520, 1435 cm-1. NMR (&, CDC13): 
0.9-1.6 (12H, m), 2.10 (4H, m), 2.63 (4H, m), 30-5.0 
(12H, m), 3.73 (3H, S), 6.60 (1H, br d, J=7 Hz), 7.16 
(1H, m). 
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EXAMPLE 75 
' 2-Pyridyl N-(N'-t-Boc-L-prolyl)methyl-N-isopropyl 
thiocarbamate 
To a solution of N-(N'-t-Boc-L-prolyl)methyl-N-iso 
propylamine (2.0 g, 7.4 mmol) and Et3N (1.2 ml, 8.6 
mmol) in THF (12 ml) at 5° C. was added a solution of 
the compound of Example 89 (1.50 g, 8.64 mmol) IN 
THF (30 ml) for 3 min. The solution was stirred at 5° C. 
for 45 min and then at r.t. for 2 hr. The precipitate was 
?ltered off and the ?ltrate was evaporated in vacuo to 
give an oil. The oil was puri?ed by silica gel column 
chromatography (solvent, 5% ethyl acetate in CHzCl2) 
to give 1.2 g of product as an oil 39.7% yield. IR (Film): 
1735 (sh), 1690, 1615, 1570, 1560 cm-1, NMR (&, 
CDCl3); 1.23 (6H, d, J =6 Hz), 1.53 (9H, S), 1.9-2.3 (4H, 
m), 3.3—3.8 (2H, m), 4.1-5.0 (4H, m), 7.33 (1H, m), 7.80 
(2H, m), 8.70 (1H, d, J=5 Hz). 
EXAMPLE 76 
2-pyridyl 
N-(L-prolylmethyl)-N-isopropylthiocarbamate 
Hydrochloride 
HCl gas was passed through a solution of the com 
pound of Example 75 (1.1 g, 2.7 mmol) in ethyl acetate 
(40 ml) at r.t. for 5 min. The solution was allowed to 
stand at r.t. for 20 min. Evaporation of the solvent gave 
a residue which was triturated with either to give a 
hygroscopic powder of product (0.7 g) 76.3% yield. IR 
(CHC13): 1740, 1645, 1605, 1545 cm-1, NMR (&, 
DMSO'd6)I 1.1-1.6 (6H, m), 1.8-2.2 (4H, m), 3.1-3.5 
(2H, m), 4.0-5.0 (4H, m), 7.5-8.2 (3H, m), 8.7 (1H, in). 
EXAMPLE 77 
2-Pyridy1 N-(Methyl 
succinyl-L-alanyl—L-alanyl-L-prolylmethyl)-N-iso 
propylthiocarbamate 
To a solution of methyl succinyl-L-alanyl-L-alanine 
(0140 g, 1.46 mmol) and N-methylmorpholine (0.16 ml, 
1.46 mmol) in THF (12 m1) at —15° C. was added a 
solution of isobutyl chloroformate (0.20 ml, 1.53 mmol) 
in THF (15 mol) for 3 min. The mixture was stirred at 
—15° C. for 10 min. To the mixture at —15° C. was 
added a suspension of the compound of Example 76. 
(0.50 g, 1.46 mmol) and N-methylmorpholine (0.19 ml, 
1.73 mmol) in acetonitrile (14 ml). The mixture was 
stirred at - 15° C. for 0.5 hr and then at r.t. for 2.5 hr. 
The reaction mixture was diluted with CHgClz. The 
organic layer was wahed with 10% aqueous citric acid, 
dried over anhydrous MgSO4, and evaporated in vacuo 
to give an oil. The oil was triturated with ether to give 
a hygroscopic powder of desired compounds. (0.16 g). 
mp. 19.5% yield. IR (CHC13): 3300, 1730, 1650, 1520 
cm-1. NMR (&, CDC13): 1.1-1.6 (12H, m), 2.03 (4H, 
m), 2.60 (4H, m), 3.5-40 (2H, m), 3.66 (3H, S), 4.1-5.2 
(6H, m), 6.76 (1H, d, J =8 Hz), 7.15-7.53 (2H, m), 7.66 
(2H, m), 8.60 (1H, brd, J =5 Hz). 
EXAMPLE 78 
2'-Benzothiazolyl 
N-(N'-t-Boc-L-proly1)methyl-N—isopropylthiolcarba 
mate 
To a solution of the compound of Example 5 (0.54 g, 
2.0 mmol) and Et3N (0.56 ml, 4.0 mmol) in THF (5 ml) 
at 5° C. was added a solution of compound 90 (0.9 g, 3.8 
mmol) in THF (5 ml). The mixture was stirred at 5° C. 
for 2 hr. The reaction mixture was diluted with CHZCIZ. 
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The organic layer was washed successively with 1120, 
10% aqueous citric acid, H20, and saturated NaCl solu 
tion, dried over anhydrous MgSO4, and evaporated in 
vacuo to give an oil. The oil was puri?ed by silica gel 
column chromatography (solvent, CHC13) to give a 
0.51 g of the compound as an oil. 55.1% yield. IR 
(Film): 1735, 1680, 1390, 1150 cm—l. NMR (&, CDC13): 
1.27 (6H, d, J=7 Hz), 1.50 (9H, S), 1.8-2.2 (4H, m), 3.50 
(2H, 111), 4.0-4.7 (4H, m), 7.20-7.66 (2H, m), 7.80-8.20 
(2H, m). 
EXAMPLE 79 
Z-Benzothizolyl 
N-(L-prolylmethyl)-N—isopropylthiocarbamate 
HCl gas was passed through a solution of the com 
pound of Example 78 (0.51 g, 1.1 mmol) in a mixture of 
ethyl acetate (7 ml) and formic acid (1 ml) at 5° C. for 5 
min. The solution was allowed to stand at r.t. for 10 min 
and then evaporated in vacuo. To the oily residue was 
added ethyl acetate and the ethyl acetate was evapo 
rated in vacuo. This operation was repeated three times. 
The residue obtained was triturated with ether to give a 
powder which was collected and washed with ether to 
give the compound (0.36 g), 82.3% yield. mp. 150°-156° 
C. IR (Nujol): 1745, 1655, 1545 cm-. NMR (&, DMSO 
d6): 1.23 (6H, d, 7 Hz), 1.7-2.2(41-I, m), 3.0-3.6 (2H, m), 
4.0-5.0 (41-1, m), 7.43-7.66 (21-1, in), 7.9-8.3 (2H, m). 
Anal. calcd. for C17H21N302Sz.HCl.Q.5I-I20: C, 49.93; 
H, 5.67; N, 10.27. Found: c, 49.94, H, 5.64; N, 10.40. 
EXAMPLE 8O 
2-Benzothiazoly1 N-(methyl 
succinyl-L-alanyl—L-alanyl-L-prolylmethyl)-N-iso 
propylthiocarbamate 
To a solution of methyl succinyl-L-alanyl-L-alanine 
(0.257 g, 0.936 mmol) and N-methylmorpholine (94.5 
mg, 0.936 mmol) in acetonitrile (4 m1) at — 15° C. was 
added a solution of isobutyl chloroformate (128 mg, 
0.936 mmol) in acetonitrile (2 ml). The mixture was 
stirred at — 15° C. and there was added a suspension of 
the compound of Example 79 (0.340 g, 0.851 mmol) and 
N-methylmorpholine (103 mg, 1.02 mmol) in acetoni 
trile (6 ml). The mixture was stirred at — 10° C. for 15 
min and then at 5° C. for 1 hr 50 min. The reaction 
mixture was diluted with CHZClZ. The organic layer 
was washed successively with 10% aqueous citric acid, 
water, and saturated NaCl solution and dried over an 
hydrous MgSO4. Evaporation of the solvent gave a 
crude oil which was puri?ed by silica gel column chro 
matography (solvent, 3% methanol in CH2C12) to give 
a 0.47 g of crystalline residue. Recrystallization of the 
crystals from tethyl acetate-hexane gave 0.35 g of de 
sired compound. 66.4% yield. mp 169°-171° C. IR 
(Nujol): 3350, 1730, 1690, 1655, 1530 cm-1. NMR (&, 
CDC13): 1.0-1.6 (12H, m), 2.1 (4H, m), 2.63 (4H, m), 
3.5-4.0 (2H, rn), 3,70 (3H, S), 4.0-5.1 (6H, m), 7.03 (1H, 
brd, J =7 Hz), 7.3-8.2, (5H, m). Anal. Calcd. for 
C23H37N5O7S2: C, 54.27; H, 6.02; N, 11.30. FOund=C, 
54.15; H, 6.03; N, 11.22. 
EXAMPLE 81 
l-Propyl-5-tetrazolyl 
N-(N'-5—Boc—L-prolyl)methyl-N-isopropylthiocarba 
mate 
To a solution of a compound 5 (2.38 g, 8.8 mmol) and 
Et3N (1.76 g, 0.0174 mol) in acetonitrile (10 m1) at 5° C. 
4,643,991 
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was added a solution of the compound of Example 91. 
(3.0 g, 0.015 mol) in acetonitrile (8 ml) for 3 min. The 
mixture was stirred at 5° C. for 1 hr and then at r.t. for 
2 hrs. The reaction mixture was evaorated in vacuo to 
give a residue which was dissolved in CH2C12. The 
CI-IgClg layer was washed with H20 and saturated NaCl 
solution, dried over anhydrous MgSO4, and evaporated 
in vacuo. The oil was puri?ed by silica gel column 
chromatography (solvent, 10% ethyl acetate in 
CH2C12) to give 1.1 g of the compound as an oil. 29.8% 
yield. IR (Film): 1735, 1680, 1390 cm—1. NMR (&, 
CDC13): 1.00 (3H, t, J=7 Hz), 1.33 (6H, d, J=7 Hz), 
1.50 (9H, S), 1.8-2.4 (6H, m), 3.53 (2H, m), 4.0-4.8 (4H, 
m), 4.37 (2H, t, J =7 Hz. 
EXAMPLE 82 
l-Propyl-S-tetrazolyl 
N-(L-proly1methy1)-N-isopropylthiocarbamate 
Hydrochloride 
HCl gas was passed through a solution of the com 
pound of Example 81 (1.1 g, 2.6 mmol) in a mixture of 
ethyl acetate (8 ml) and formic acid (6 ml) ar r.t. for 3 
min. The solution was allowed to stand at r.t. for 10 
min. The reaction mixture was evaporated in vacuo to 
give an oil. To this oil was added ethyl acetate and the 
ethyl acetate was evaporated in vacuo. The oil was 
triturated with ether to give a'hygroscopic powder of 
90 (0.4 g). NMR (&, DMSO-d6)=0.9-1.6 (9H, m), 
1.7-2.3 (6H, m), 3.2-4.0 (2H, 111), 4.0-5.0 (6H, m). 
EXAMPLE 83 
1-Propyl-5-tetrazolyl N-(methyl 
succinyl-L-analyl-L-alany1-L-prolylmethyl)-N-iso 
propylthiocarbamate 
To a solution of methyl succinyl-L-Alanyl-L-alanine 
(0.325 g, 1.31 mmol) and N-methylmorpholine (0.132 g, 
1.31 mmol) in THF (3 ml) at -l5° C. was added a 
solution of isobutyl chloroformate (0.179 g, 1.31 mmol) 
in THF (1 ml). The mixture was stirred at — 15° C. for 
10 min. To the mixture was added a suspension of the 
compound of Example 83 (0.35 g, 0.93 mmol) and N 
methylmorpholine (0.15 g, 1.5 mmol) in acetonitrile (4 
ml). The mixture was stirred at — 10° C. for 0.5 hr and 
then at 5° C. for 4 hrs. The reaction mixture was diluted 
with CHgCl. The organic layer was washed succes 
sively with 10% aqueous citric acid, water and satu 
rated NaCl solution, dried over MgSO4, and evaporated 
in vacuo. The oil obtained was puri?ed by silica gel 
column chromatography (solvent, 3% methanol in 
CHCl3) to give 0.13 g of the compound as an oil. The oil 
was crystallized from ethyl acetate-hexane to give 39 
mg. 7.0% yield, mp 107°-108° C. IR (Nujol): 3350, 
1735, 1685, 1655, 1530 cm-1. NMR (& CDC13): 1.00 
(3H, t, J =7 Hz), 1.0-1.7 (12H, m), 1.7-2.3 (6h, m), 2.66 
(4H, m), 3.5-4.0 (2H, m), 3.70 (3H S), 4.0-5.1 (8H, m), 
6.83 (1H, d, 8 Hz), 7.50 (1H, m). 
EXAMPLE 84 
N-N’-t-Boc-L-pro1y1)methyI-N-Z-propynylamine 
To a solution of (N-t-Boc-L-prolyl)chloromethane 
(2.0 g, 8.1 mmol) in ether (50 ml) at 5° C. was added 
2-propynylamine (2.2 ml, 0.032 mol). The solution was 
stirred at 5° C. for 1.5 hr and then at r.t. for 1 hr. The 
precipitate was ?ltered off and washed with ether. The 
?ltrate was evaporated in vacuo to give an oil. The oil 
was puri?ed by silica gel column chromatography (sol 
vent, 3% methanol in CHC13) to give 1.1 g of the com 
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pound as an oil. 51% yield, IR (Film): 3200-3500, 1690, 
1400 cm—l. NMR (&, CDC13): 1.43 (9H, 8), 1.7-2.1 
(4H, m), 2.30 (1H, brS), 3.3-3.8 (6H, m), 4.3 (11-1, m). 
EXAMPLE 85 
p-Nitrophenyl 
N-(N’-5-Boc-L~prolyl)methyl-N-2-propynylcarbamate 
To a solution of the compound of Example 84 (1.0 g, 
3.76 mmol) and Et3N (0.65 ml, 4.7 mmol) in THF (12 
m1) at 5° C. was added a solution of p-nitrophenyl chlo 
roformate (0.75 g, 3.72 mmol) in THE (4 ml). The mix 
ture was stirred at 5° C. for 1 hr and then at r.t. for 2 hr. 
The reaction mixture was ?ltered and the ?ltrate was 
evaporated in vacuo. The oil was purified by silica gel 
column chromatography (solvent, CHC13) to give an oil 
(1.60 g). 98.9% yield, IR (Film): 1730, 1680, 1610, 1590 
cm—1. NMR (&, CDC13): 1.43 (9H, S), 2.0(41-1, m), 2.43 
(1H, brS), 3.6-4.8 (71-1, m), 7.43 (2H, m), 8.33 (2H, brd, 
J = 8 Hz). 
EXAMPLE 86 
P-Nitrophenyl 
N-(L4prolylmethyl)-N-2-propynylcarbamate 
Hydrochloride 
HCl gas was passed through a solution of the com 
pound of Example 85. (1.40 g, 3.25 mmol) in ether (40 
ml) at r.t. for 5 min. The solution was allowed to stand 
at r.t. for 15 min. The reaction mixture was evaporated 
in vacuo to give a residue. Trituration of the oil with 
ether gave a powder (0.36 g) of the compound. 30.1% 
yield, mp 141°-152° C. IR (Nujol): 3300, 1740, 1720, 
1610, 1590, 1515 cm-1. NMR (&, DMSO-d6): 2.0 (4H, 
m), 2.40 (1H, brS), 3.3-3.7 (2H, m), 4.0-4.8 (5H, m), 7.40 
(2H, brd, J =8 Hz), 8.30 (2H, d, J =8 I-Iz). 
EXAMPLE 87 
-p-Nitrophenyl N-(methyl 
succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N 
propynylcarbamate 
To a solution of methyl succinyl-L-alanyl-L-alanine 
(0.27 g, 0.99 mmol) and N-methylmorpholine (0.11 ml, 
1.0 mmol) in THF (12 ml) at -15° C. was added a 
solution of isobutyl chloroformate (0.13 g, 0.95 mmol) 
in THF. The mixture was stirred at — 15° C. for 15 min. 
To the mixture was added a mixture of the compound 
86 (0.35 g, 0.95 mmol), N-methylmorpholine (0.11 ml, 
1.0 mmol), and bis(trimethylsilyl)acetamide (1.5 ml) in 
THF (14 ml). The mixture was stirred at — 15° C. for 1 
hr. and then at r.t. for 2.5 hr. The reaction mixture was 
diluted with CH2C12. The organic layer was washed 
with 10% aqueous citric acid, dried over anhydrous 
MgSO4, and evaporated in vacuo to give an oil. The oil 
was puri?ed by silica gel column chromatography (sol 
vent, 5% methanol in CHC13) to give an oil. Trituration 
with ether gave a powder (0.21 g) of the compound. 
37.7% yield. mp. 160°-163° C. IR (Nujol): 3340, 1740, 
1690, 1655, 1635, 1595, 1520 cm-1. NMR (&, CDC13): 
1.33 (6H, d, J =7 Hz), 2.03 (4H, m), 2.40(1I-1, brS), 2.60 
(4H, m), 3.5-4.0 (2.H, m), 3.70 (3H, S), 4.1-5.0 (7H, m), 
6.40 (1H, m), 7.10 (1H, d, J=7 Hz), 7.33 (2H, in), 8.30 
(2H, d, J =9 Hz). 
EXAMPLE 88 
2-Thioxo 3-thiazolidinecarbonyl chloride 
A solution of Z-mercaptothiazoline (2.0 g, 0.0168 
mmol) and Et3N (2.9 ml, 0.021 mol) in THE (30 ml) was 
25 - - 
added dropwise to a solution of phosgene (2.37 g, 
0.0239 mol) in toluene (12 ml) at 5° C. for 7 min. The 
mixture was stirred at 5° C. for 5 min and then ?ltered 
to remove the precipitate. The ?ltrate was evaporated 
in vacuo to give a crystalline residue. To the residue 
was added ether ( 10 ml) and the ether was evaporated in 
vacuo. This operation was repeated twice. 2-Thioxo-3 
thiazolidinecarbonyl chloride (2,0 g) was obtained as a 
solid. 65.5% yield. IR (Nujol). 
EXAMPLE 89 
Z-Pyridyl thiochloroformate 
A solution of Z-mereaptopyridine (1.50 g, 0.0135 mol) 
and Et3N (2.5 ml, 0.018 mol) in THF (24 ml) was added 
dropwise to a solution of phosgene (1.53 g, 0.015 mol) in 
toluene (8 ml) at 5° C. for 6 min. The mixture was 
stirred at 5° C. for 5 min and then at r.t. for 5 min. The 
reaction mixture was ?ltered and the ?ltrate was evapo 
rated in vacuo. To the residue was added ether and the 
ether was evaporated. This operation was repeated 
twice. An oil of the compound (1.5 g) was obtained. 
63.9% yield. IR (Film): 1765 c~1. 
EXAMPLE 90 
2-Benzothiazolyl thiochloroformate 
A solution of Z-mercaptobenzothiazole (0.669 g, 4.0 
mmol) and Et3N (0.61 ml, 4.4 mmol) in THF (5 ml) was 
added to a solution of phosgene (0.59 g, 6.0 mmol) in 
toluene (3.1 ml) at 5° C. for 15 min. To the mixture was 
added acetonitrile (3 ml). The mixture was stirred at 5° 
C. for 0.5 hr. The precipitate was ?ltered and washed 
with THF. The ?ltrate was evaporated in vacuo to give 
' a solid (0.9 g). IR (Nujol)=l775, 1605 cm*1. 
EXAMPLE 91 
l-Propyl-S-tetrazolyl thiochloroformate 
A solution of S-mercapto-l-propyltetrazole (2.5 g, 
0.0174 mol) and Et3N (2.65 ml, 0.0101 mol) in acetoni 
trile (10 ml) was added to the solution of phosgene (2.58 
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g, 0.0260 mol) in toluene (13.5 ml) at 5° C. for 50 min. ' 
The mixture was stirred at 5° C. for 50 min. The precipi 
tate was ?ltered off and washed with THF. The ?ltrate 
was evaporated in vacuo to give an oil (3.1 g). IR 
(Film): 1775, 1720 cm- 1. NMR (&, CDCl3)= 1.00 (3H, 
t, J =7 Hz), 2.10 (2H, m), 4.50 (2H, m). 
EXAMPLE 92 
N-Tri?uoroacetyl-L-alanyl-L-alanine 
This compound was prepared according to the 
method by Schallenberg et al [E. E. Schallenberg and 
M. Calvin, J. Amer. Chem. Soc. 77, 2779 (1955); J. L. 
Dimicoli et a1. Biochemistry 15, 2230 (1976)]; yield based 
‘on alanyl-a-alanine, 71.3%; mp 225°—235° C. (dec) 
NMR (DMSO-d6 & 1.42 (d, J =7 Hz, 3H), 1.46 (d, J =7 
Hz, 3H), 4.54 (1, J =7 Hz, 2H), 7.92 (d, J =8 Hz, 1H), 
8.46 (d, J.=7 Hz, 1H); IR (Nujol) 3330, 3310, 3270, 1705, 
1665, 1545 em-l. / 
EXAMPLE 93 
Penta?uorophenyl 
N-(tri?uoroacetyl-L-alanyl-L-alanyl-L-prolylmethyl) 
- N-isopropylcarbamate 
This compound was prepared in a similar manner as 
Example 10 colorless powder; yield 20.3%, mp 85°-88° 
C., NMR (CDC13), & 0.9-1.9 (m, 12H), 1.9-2.5 (m, 4H), 
3.3-5.0 (m, 8H), IR (Film) 3420 (b), 1715, 1670, 1555 
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cm- 1. Anal. calcd for C24H26N4F3O6: C, 46.61; H, 4.24; 
N, 9.06. Found C, 46.74, H, 4.27, N, 9.04. 
EXAMPLE 94 
Hepta?uorobutyl chloroformate 
Triethylamine (3.66 ml, 26.3 mmol) was added drop 
wise to a solution of hepta?uorobutanol (3.1 ml, 25 
mmol) and phosgene (3.3 g, 30 mmol) in benzene (26 ml) 
at 5° C. Themixture was stirred at 5° C. for 30 min and 
at room temperature for 2 h, ?ltered and distilled. The 
product distilled with benzene and was was used in the 
next step without further puri?cation. NMR (CDC13) & 
4.70 (5, 2H, J=12.5 Hz; IR (Film) 1785 cm-1. 
EXAMPLE 95 
Penta?uorophenyl chloroformate 
This compound was prepared according to the proce 
dure in Example 94: IR (Film) 1800, 1525 cm--‘. 
EXAMPLE 86 
l-Phenyl-S-tetrazolyl chlorodithioformate 
To a solution of thiophosgene (1.29 g, 0.0112 mol) in 
'THF (40 ml) at 5° C. was added a solution of l-phenyl 
lH-tetrazole-S-thiol (2.0 g, 0.0112 mol) and Et3N (1.94 
ml, 0.0134 mol) in THF (30 ml). The mixture was stirred 
at 5° C. for 30 min and then at r.t. for 1 hr. 20 min. The 
precipitate was ?ltered and washed with THF. The 
?ltrate was evaporated in vacuo. To the obtained resi 
due was added ether and the insoluble material was 
?ltered off. The ?ltrate was evaporated in vacuo to give 
a solid which was recrystallized from CHCl3--hexane. 
0.91 g of the compound was obtained. 27.6% yield. 1R 
(Nujol): 1725, 1585 cm-l. 
EXAMPLE 97 
l-Phenyl-S-tetrazolyl 
N-(N’-5-Boc-L-proly1)methyl-N-isopropyldithiocarba 
mate 
To a solution of compound 5 (1.30 g, 4.81 mmol) and 
Et3N (0.83 ml, 5.7 mmol) in THF (14 ml) at 5° C. was 
added a solution of the compound of Example 96 (1.40 
g, 4.77 mmol in THF (14 ml) for 10 min. The solution 
was stirred at 5° C. for 2 hr and then at r.t. for 2 hr. The 
precipitate was ?ltered and washed with THF. The 
?ltrate was evaporated in vacuo and the obtained oil 
was puri?ed by silica gel column chromatography (sol 
vent, CHC13) to give 1.30 g of the compound as an oil. 
51.8% yield. IR (Film): 1740, 1690, 1595, 1395 cm—l. 
NMR (&, CDC13): 1.0-1.6 (6H, m), 1.50 (9H, S), 1.8-2.3 
(4H, m), 3.3-4.8 (6H, m), 7.63 (5H, S). 
EXAMPLE 98 
l-Phenyl-S-tetrazolyl 
N-(L-prolylmethyl)-N-isopropyldithiocarbamate 
Hydrochloride 
HCl gas was passed through a solution of compound 
97 (1.20 g, 2.28 mmol) in ether (50 ml) at r.t. for 8 min. 
The solution was allowed to stand at r.t.-for 15 min. The 
reaction mixture was evaporated in vacuo to give an oil 
of the compound (0.85 g), 87.4% yield. NMR (&, 
DMSO-d6): 1.0-1.6 (6H, m), 1.8-2.3 (4H, m), 3.348 
(6H. m), 7.73 (5H, s). 
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EXAMPLE 99 
l-Phenyl-S-tetrazolyl N-(methyl 
succinyl-L-alanyl-L-alanyl-L-prolylmethyl)-N-iso 
propyldithiocarbamate 
To a solution of methyl succinyl-L-alanyl-L-alanine 
(9.60 g, 2.20 mmol) and N-methylmorpholine (9.24 ml, 
2.19 mmol) in THF (20 ml) at — 15° was added a solu 
tion of isobutyl chloroformate (0.28 ml, 2.13 mmol) in 
THF (5 ml). The mixture was stirred at — 15° C. for 15 
min. To the mixture was added a mixture of compound 
98 (0.80 g, 1.86 mmol), N-methylmorpholine (0.24 ml, 
2.19 mmol), and bis(trimethy1silyl)acetamide (2 ml) in 
THF (14 ml). The mixture was stirred at - 15C for 0.5 hr 
and then at r.t. for 2 hr. The reaction mixture was di 15 
- e “ ' '28 
luted with CI-ICl3. The organic layer was washed with 
10% aqueous citric acid, dried over anhydrous MgSO4, 
and evaporated in vacuo to give an oil. The oil was 
crystallized from CHClg-hexane to give crystals of 
compound 99. NMR (&, CDCl3); 0.9-1.6 (12H, m), 2.0 
(4H, m), 2.53 (4H, m), 3.5-3.8 (2H, m), 3.63 (3H, s), 
4.0-5.0 (6H, m), 7.0 (1H, m), 7.13-7.8 (5H, m). 
The procedures described in Schemes I and II above 
and the following Schemes III, IV, V and VI were 
followed in preparing the compounds of the working 
examples described above. Set forth hereinafter are 
Schemes III, IV, V and VI with the compounds pre 
pared in the examples being indicated. The compounds 
of the intermediates and ?nal products are identified by 
example numbers adjacent the de?nitions of R and R’. 



4,643,991 
-continued 
Scheme Vl 
cmcnm N-N 
O l MeOSuc-Ala—Ala 
II N s—< HCLN \u/ 
s N N 
99 
cmcnm N — N 
II N s—< MeO-Suc-Ala-Ala-N \H/ 
S N _ N 
99 
As pointed out above, the compounds of the inven 
tion are useful as elastase inhibitors. To evaluate the 
compounds, the inhibitory activity of the compounds 
were tested in vitro against the serine dependent proteo 
lytic enzymes, trypsin, chymotrypsin and porcine pan 
creatic elastase. All three enzymes belong to the family 
of serine proteases where the catalytic residues are com 
posed of a triad of amino acid residues, serine, histidine 
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and aspartic acid that actually perform the peptide bond 
hydrolysis. In addition to the catalytic residues, the 
active site is composed of an extended substrate binding 
site that consists of a primary substrate binding site S], 
and various subsites on either side of the scissile bond. 
The terminology of Schechter and Berger, Biochem. 
Biophys. Res. Commun., 27, 157 1980) is used where 
S2-S1-S1'-S2’ refer to subsites on both sides of the cata 
lytic site of the enzyme and the notation P on the sub 
strate (or inhibitor) denotes amino acid residues which 
bind to these enzyme subsites, such that Pl-Pl’ repre 
sents the bond which is cleaved. Substrate speci?city 
studies with HL elastase, Powers et al, Biochem, Bio 
phys, Acta., 485, p. 156, (1977), have shown that sub 
strates with the sequence MeOSuc-Ala-Ala-Pro-Val 
(representing P5-P4-P3-P2-P1 are highly reactive with 
the enzyme. The same sequence, although not idea] 
with PP elastase, was found to react with it effectively. 
In fact, HL elastase is similar to the more widely studied 
PP elastase in many respects. They are both serine pro 
teases that show esterase activity toward synthetic sub 
strates such as Boc-Ala-ONp and are both inhibited by 
cu-anti-trypsin. Furthermore, the natural substrates of 
these enzymes are very similar. 
The results of these evaluations are set forth in the 
following Tables 1, 2, and 3. The compounds tested as 
shown in Tables 1, 2, 3, and 4 were prepared as de 
scribed above. 
TABLE 1 
Peptidyl Carbamates (ROCONR'R") where NR'R" is a Polypeptide 
Effect of changes in P)’ on inhibitory activity towards PP elastase“) 
Compound Ki 
No. (FM) Comments mp” (°C.) 
10 P1’ 42.5 + 153-163 
MeOSuc-Ala-A1a-Pro—CH2-N—CO—O N02 
ll 32.5 + 60-65 
MeOSuc-Ala-Ala-Pro-Clh-N-CO-O 
58 F F 37.5 + ‘152-154 
MeOSuw-Ala-Ala-Pro-CI-b-N'-'CO'-'O F 
F F 
61 MeOSuc-Ala-Ala—Pro-—CH2—N—CO—O CHZCFZCFZCH + 165466 
64 — 125-127 
Me0Suc-Ala-—Ala—Pro-Clh-N-CO-SCH; 
18 N __ N 14.8 + 84-87 
III-N 
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TABLE l-continued 
Peptidyl Carbamates (ROCONR'R") where NR'R” is a Polypeptide 
Effect of cha_nges in P1’ on ' Libitory activity towards PP ‘ ‘ ‘U 
Compound Ki 
No. (HM) Comments mp” (°C.) 
— ~50 
('INONE OF THE LISTED COMPOUNDS EXHIBITED INHIBITION TOWARDS TRYPSIN AND CHYMOTRYPSIN 
I 
+ AT LEAST 70% INHIBITION OF PP ELASTASE OBSERVED IN 30 MIN AT -r[-El]—— = 260, [I] ~ 150 PM 
— NO INHIBITION OF PP ELASTASE AT [I] < 150 ILM USING [E] = 0.61 MM 
"ALL COMPOUNDS WERE NOVEL AND WERE IDENTIFIED BY SPECTRAL DATA AND ELEMENTAL ANALYSES‘ 
TABLE 2 
Peptidyl Carbamates (ROCONR’R") where R'R"N is a Polypeptide: 
Effect of changes in P] on inhibitory activity towards PP elastase.(') 
Compound _ Ki 
No. (pM) Comments mp” (“C.) 
10 P1 42.5 + 153-163 
MeOSuc-Ala-Ala—Pro-CH2—N—CO—O@ N02 
29 30.5 + 161-166 
MeOSue-AIa-AIa-Pro-CI-Ir-N—CO—O@ N02 
32 + 155-160 
Meosuc-Ala-A1a-Pro-cii2—N—co—0—@- N02 
68 + 105-110 
MeOSuc-Ala-Ala—Pro—CI-I2-I;I—CO—O—©>— N02 
72 ' — 147-151 
MeOSuc—A1a—Ala-Pro-CI-Ir-NN-CO-O N02 @
(“NONE OF THE LISTED COMPOUNDS EXHIBITED INHIBITION TOWARDS TRYPSIN AND CHYMOTRYPSIN 
I 
+ AT LEAST 70% INHIBITIONOF PP ELASTASE OBSERVED IN 30 MIN ATL = 260, [I] ~ 150 ILM 
[E] 
- NO INHIBITION OF PP ELASTASE AT [I] < 150 ILM USING [E] = 0.61 pM 
"ALL COMPOUNDS WERE NOVEL AND WERE IDENTIFIED BY SPECTRAL DATA AND ELEMENTAL ANALYSIS. 
TABLE 3 
Peptidyl Carbamates (ROCONR'R") where R'R"N is a polypeptide 
Effect of Variations in P5 and P3 on inhibitory activity towards PP elastase 
Compound 7 _ Ki 
No. (p‘M) Comments mp‘1 (°C.) 
58 I F F 37.5 + 152-154 
P5 P3 
MeOSue-AIw-Ala-Pro-CI-h-N-CO-O F 




